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ABSTRACT
Little is known about the effect of different modes of expression of an antigen in 
rBCG on immune response. An appropriate wing of the immune system, with 
different degrees, is activated upon encounter with a foreign antigen. Knowledge of 
these responses is vital to the development of future recombinant vaccine.
Various E. co//-mycobacterial species shuttle vector constructs were made using a 
combination of mycobacterial promoters and signal sequences. Thus enabling 
foreign antigens to be expressed cytoplasmically or secreted outside rBCG as native 
proteins or membrane-associated lipoproteins. A pivotal study using an E. coli 
P-lactamase as a reporter gene is described for the evaluation of the strength of 
promoter and signal sequence constructs both in vitro and most importantly in vivo 
using the mouse macrophage cell line J-774. Expression of the diphtheria toxin 
fragment B as a foreign antigen was detected in vitro with all constructed plasmid 
vectors in rBCG using a western blot as a means of detection.
It was observed that all hsp60 promoter-based constructs exhibited a high frequency 
with variable degree of plasmid DNA deletions Using three different rBCG 
substrains, the BCG Tokyo was found to be more stable (P<0.01) and exhibited less 
degree of deletion (P<0.001) compared to either BCG Moreau or BCG Pasteur. 
Sequence analysis of deleted plasmid DNA revealed a specific region common with 
nearly all plasmid deletions. Such a region of the DNA was found to correspond to 
the first transcriptional starting site of the hsp60 promoter. Furthermore no 
differences were observed in the level of expression among the three-rBCG 
substrains, retaining plasmid DNA, when detected by immunoblotting.
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Introduction
Chapter 1
1.0. Introduction
Since its discovery, by Robert Koch (1882), Mycobacterium tuberculosis continues 
to be the number one killer in the world among infectious diseases. Each year 54 
million people are infected with M. tuberculosis, 1 million develop clinical diseases 
and 3 million people die of tuberculosis (Kochi, 1994). Indeed, at current rates, it has 
been estimated that up to 500 million people will suffer from tuberculosis in the next 
50 years and that the infection will prove fatal to more than 200 million of them. 
These frightening figures prompted the World Health Organization (WHO) to 
declare, for the first time in the WHO’s history, that tuberculosis is a global health 
emergency (Kochi, 1994).
1.1. Mycobacteria and disease
Robert Koch identified M. tuberculosis as the causative agent of tuberculosis and a 
decade later; Hansen identified the cause of another feared disease, leprosy, which is 
caused by M  leprae. These two mycobacteria are the most important members of the 
Mycobacterium genus because of the nature of the disease they cause. However, 
other Mycobacterium species are also pathogenic to man such as M  kansasii and M. 
avium-intracellulae (Roberts et al., 1987), which cause disseminated infections in 
immunocompromised patients (Wayne, 1985). Othsr Mycobacterium species such as 
M. maritim and M  ulcerans grow better at cool temperatures and are generally 
restricted to the skin surfaces.
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M. tuberculosis in droplets (1-5 pm in diameter) is inhaled and reaches the alveoli. 
Tuberculosis results from the establishment of infection, proliferation of virulent 
organisms and interactions with the host immune system. The host’s level of 
resistance or hypersensitivity greatly influences the development of the disease. 
Chiefly, the number of mycobacteria in the inocula (and their subsequent 
multiplication) and the resistance or hypersensitivity of the host influence 
development of lesions and their healing or progression.
Since the tubercle bacillus can infect every organ system, its clinical manifestations 
are protean. Fatigue, weakness, weight loss, and fever may be signs of tuberculous 
disease. Pulmonary involvement gives rise to chronic coughing, blood in sputum 
usually being associated with far-advanced lesions. Meningitis or urinary tract 
involvement can occur in the absence of other signs of tuberculosis. Bloodstream 
dissemination leads to miliary tuberculosis with lesions in many organs and a high 
mortality rate.
1.2. Pathogenesis of tuberculosis
M  tuberculosis is inhaled as droplet nuclei, each containing one to three bacteria. 
These small particles are carried via the airstreams and distributed to all regions of 
the lung (Wiegeshaus et al,, 1989). The mycobacteria are taken up by alveolar 
macrophages mediated by complement and mannose receptors expressed at the 
surface of differentiated macrophages (Schlesinger, 1993), and possibly by a recently 
identified macrophage cell entry protein expressed by virulent mycobacteria (Riley,
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1995). The bacteria may either be destroyed or start to multiply after a lag period of 
few days. Pro-inflammatory cytokines (IL-1, IL-6, TNFa) and chemokines 
(macrophage inflammatory proteinl, interferon inducible protein 10) secreted fi-om 
the infected macrophage lead to the recruitment of monocytes and lymphocytes from 
the blood and the development of the inflammatory process (Murray et al., 1996; 
Taub et al., 1993). This first phase of the infection is considered to be a symbiotic 
relationship between host and parasite. The host is apparently unaffected by the 
infection and the macrophages have not yet been activated by cytokines and will 
therefore not efficiently inhibit mycobacterial growth.
In the mouse model of TB the first signs of substantial specific immunity have been 
reported to emerge after about two weeks of infection (Andersen et al., 1991; Orme, 
1987), and involve the triggering of cytokine release from specific T lymphocytes 
(Andersen et al., 1992; Andersen et al., 1995; Orme et al., 1993). The cytokines 
activate the bacteriostatic activity of the macrophage and accelerate the lymphocyte 
recruitment. As the process progresses, monocytes mature into epithelial cells and 
multi-nucleated giant cells surrounded by T lymphocytes, thereby becoming a 
granuloma (Turk & Narayanan, 1982). It has been demonstrated that TNFa is a 
cytokine of major importance for this granuloma formation and in vivo neutralization 
of TNF during infection results in a lack of granuloma formation and uncontrolled 
bacterial multiplication (Kindler et al., 1989).
A dynamic balance of host and parasite factors determines the outcome of disease. In 
a resistant individual a high level of activity may be reached rapidly and the disease
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is consequently controlled in the asymptomatic stage. In the susceptible host, by 
contrast, the process of bacterial multiplication and cellular recruitment continues, 
the primary lesion enlarges and some bacteria are transported to the regional lymph 
nodes, giving rise to a granulomatous reaction. The combination of the primary 
lesion and changes in the regional lymph node is termed a primary complex. As the 
disease continues, the amplified immune reaction leads to intense inflammation, 
tissue destruction, caseous necrosis and the formation of cavity lesions (Dannenberg,
1991). At this stage, lysis of the macrophages may result in the release of viable 
bacteria into the blood and the generation of metastatic foci in various organs 
(Wiegeshaus et al., 1989). From studies of the location of single cavity lesions in the 
lung, the apical lung zone appears to be a particularly vulnerable site that allows 
bacterial multiplication either after haematogenous dissemination or directly after 
primary implant (Smith & Wiegeshaus, 1989); if the host controls the infection, the 
lesions are encapsulated, sterilized and left as calcified scars. The bacteria may be 
held in stasis, but survive for many years until an eventual later down-regulation of 
host activity, e.g. as a consequence of immunosuppression, allows a continued 
multiplication. This event is called the endogenous reactivation of TB (Smith & 
Wiegeshaus, 1989).
1.2.1. Interaction Between Macrophages & Mycobacteria
12.1.1. General Introduction
Although both virulent and avirulent mycobacteria are internalised by monocytes and 
macrophages (Ramakrishnan & Falkow, 1994; Swartz et al., 1988), only pathogenic 
mycobacteria survive and replicate intracellularly (McDonough et al., 1993).
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M. tuberculosis is resistant to macrophage killing, and its survival during 
phagocytosis and its subsequent multiplication within these professional phagocytes 
are critical to its pathogenesis. A variety of mechanisms have been suggested to 
contribute to the survival of M  tuberculosis within macrophages (Shinnick et al.,
1995), including inhibition of phagosomes (Sturgill-Koszycki et al., 1994; Gomes et 
al., 1999) resistance to killing by reactive oxygen intermediates (Lowrie, 1983) and 
reactive nitrogen intermediates (Chan et al., 1992; MacMicking et al., 1997), and 
modification of the lipid composition of the mycobacterial cell membrane, thereby 
altering its capacity to interact with immune or inflammatory cells (Ilangumaran et 
al., 1995). However little progress has been made in identifying the genes and their 
corresponding products responsible for these properties.
1.2.1.2. Port of Entry & Initial Interaction
Macrophages play a key role in infection with M  tuberculosis', the normal portal of 
entry of the organism into the host is via alveolar macrophages, where the organism 
can survive asymptomatically, sometimes for many years. Occasionally, in a 
proportion of infected individuals, after varying periods of time and in response to 
poorly understood factors, these intercellular bacilli start to divide, escape the 
macrophage environment and cause clinical disease. Thus the initial interaction with 
the alveolar macrophage is likely to play a key role in determining the outcome of 
infection, and an understanding of these early events at the molecular level, could 
provide new intervention strategies.
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1.2.1.3. Entry into the macrophages
The initial entry of M  tuberculosis into host macrophages involves a number of 
specific receptor-ligand interactions. The most widely studied of these involve 
complement receptors CRl, CR3 and CR4 (Schlesinger et al, 1990; Schlesinger & 
Horwitz, 1991), InM  leprae, the species-specific glycolipid (PGL-1) binds to the C3 
receptor and mediates phygocytosis. It seems likely that components of 
M  tuberculosis play a similar role. In addition to complement receptors, mannose 
receptors have been found to play a role in mediating uptake of M  tuberculosis. 
Interestingly, it appears that virulent strains involve both mannose and complement 
receptors, while avirulent strains utilize only complement receptors (Schlesinger,
1993). Further work has identified mannose units at the terminal end of LAM as the 
mycobacterial ligand for the mannose receptor (Schneider et a l, 1994),
12.1.4. Intracellular fate of M tuberculosis
One area of intense research in TB has focused on how mycobacteria avoid 
destruction by the immune system. Macrophages bind and ingest M  tuberculosis, 
resulting in any one of multiple fates: (i) the bacillus can be destroyed, (ii) it can 
persist in a viable state, (iii) it can proliferate and lead to the death of the macrophage 
and dissemination of the bacteria, or (iv) it can stimulate macrophage apoptotic 
bodies and lead to the containment of bacilli within apoptotic bodies. This latter fate 
has been demonstrated for bothM  avium (Fratazzi et a l, 1997) andM tuberculosis 
(Fratazzi a/., 1999).
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After M. tuberculosis has been phagocytosed by macrophages, the bacilli are capable 
of influencing their transport through the macrophage endosomal-lysosomal system, 
thereby preventing their delivery to mature degradative lysosomes. By an unknown 
mechanism, the M  tuberculosis bacilli can inhibit the maturation of the phagosome, 
arresting it in the early endosomal stage. The M  tuberculosis blocks delivery of the 
proton-ATPases and may also prevent removal of the Na+/K+-ATPase, which 
counteracts the proton-ATPase pump. These effects combine to prevent the 
M  tuberculosis-contdxms\§, phagosome from acidifying to the mature lysosomal pH 
of 5.2, instead remaining at pH 6.3 (Strohmeier & Fenton, 1999). The 
M  tuberculosis-(xtnXdimn% phagosome does acquire some maturational markers such 
as procathepsin D and lysosome-associated membrane glycoproteins, molecules 
associated with late endososomal compartments (Strohmeier & Fenton, 1999). 
However, due to the elevated pH, the procathepsin D fails to be cleaved to its mature 
form. The delivery of only the proenzyme form of procathepsin D to the 
M. tuberculosis phagosome suggests that this compartment may continuously receive 
new material from the host cell’s synthetic pathway, and that this phagosome does 
not fuse with a preformed lysosomal-like vesicle. M. tuberculosis phagosomes fail to 
acquire acid phosphatases, further supporting the observation that the phagosome 
does not fuse with mature lysosomes (Strohmeier & Fenton, 1999).
However, the M  tuberculosis phagosome is not a static compartment within the 
macrophages (Russell et al., 1997). Rather, it continually interacts with the 
endosomal system. Transfer receptor, a stable constituent of the early and recycling 
endosomal apparatus, and exogenously added transferrin, can be observed trafficldng
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through the M  tuberculosis phagosome, as can other soluble factors such as 
horseradish peroxidase (Clemens, 1996). Such a dynamic exchange with the sorting 
pathway allows the M. tuberculosis bacilli to obtain nutrients required for their 
continued survival and may provide a pathway for release of the virulence factors 
they synthesize (Gomes et al, 1999).
Mycobacterial infection of alveolar macrophages has been reported to induce 
apoptosis in the infected cells (Keane et al, 1997; Rojas et a l, 1998). Both 
M  tuberculosis H37Ra and H37Rv significantly increased macrophage mortality via 
programmed cell death. This response was mediated, at least in part, by TNFa. Cell 
survival was enhanced when anti-TNFa antibodies were used to treat the infected 
cells. The cytolytic mechanism induced by M  tuberculosis was shown to be 
apoptosis, and the same response was observed in caseating granulomas from TB 
patient lung tissue samples. Although neither beneficial nor detrimental effects of 
M. tuberculosis-mdncQd macrophage apoptosis have been described in vivo, this 
process of programmed cell death may benefit the host. It has been proposed that 
apoptotic bodies that contain viable M. tuberculosis do not release the organism and 
do not provide an environment favourable for M. tuberculosis growth. Furthermore, 
these apoptotic bodies may be phagocytosed by uninfected macrophages, and the 
mycobacteria contained within are more likely to be destroyed (Fratazzi et a l, 1997). 
Thus, M  tuberculosis -induced macrophage apoptosis may benefit the host by 
preventing the dissemination of intracellular bacteria (Strohmeier & Fenton, 1999).
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1.3. T lymphocytes and antigen presentation
Generally, it is believed that acquired resistance to mycobacteria is a cell-mediated 
process that starts when sentisitized thymus-dependent lymphocytes recognize 
bacterial antigens on antigen-presenting cells. In murine models, at least some degree 
of immunity can be adoptively transferred to naive animals by T cells that belong to 
two distinct subsets of lymphocytes with differing antigens receptors and effectors 
fiinctions. One subset releases interleukins that attract blood-borne phagocytes to the 
site of infection and augment their antimicrobial activity. The other subset kills 
infected macrophages (De Libero & Kaufmann, 1986; Orme, 1987; Orme & Collins, 
1984; Pedrazzini etal., 1987).
A number of distinct glycoproteins now referred to as clusters of differentiation (CD) 
antigens are present on the surface of lymphocytes and on other cells of the immune 
system. Some of these glycoproteins can be used as phenotypic markers to identify a 
population and subsets of lymphocytes in blood and tissues. Two of these CD 
antigens are widely known and can be used to identify subpopulations of T 
lymphocytes with different functions. The 57-kDa glycoprotein called CD4 is 
expressed on T cells of the ‘helper’ variety, and the 32-kDa glycoprotein called CD8 
is present on T cells belonging to the ‘suppressor’ and ‘ cytotoxic’ subsets.
Unlike the immunoglobulin receptor on B cells, which can recognize free antigens, T 
lymphocytes only recognize antigens associated with glycoproteins encoded by 
major histocompatibility class (MHC) genes on other cells (Kronenberg et al., 1986; 
Unanue et al., 1984). Most cell types have MHC class I products on their surface and
1 0
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can present antigen to CDS T cells. In contrast, only a limited number of cell types 
express MHC class II molecules and can present antigen to CD4 T lymphocytes. The 
latter type of antigen-presenting cell (APC) includes macrophages, dendritic cells of 
lymph nodes, Langerhans cells of the skin, Kuppfer cells of the liver, B-lymphocytes 
and activated T cells.
And, unlike B cells, most T cells do not recognize protein antigens in their native 
state; rather, antigens must undergo various degrees of processing by APCs to 
stimulate T cells (Unanue et al., 1984). Sometimes, processing consists of a mere 
conformational change in the tertiary structure of the molecule; most often, 
proteolytic degradation into smaller peptide fragments is required. Soluble proteins 
endocytosed by APCs are processed in acidified vesicles; these fuse with other 
vesicles containing MHC class II molecules and are then transported to and 
expressed on the surface of the cell. Processing of antigen for presentation to CD8^ T 
cells appears not to require acidification. It is believed that vesicles carrying MHC 
class I determinants pick up degradation products of intercellular proteins. Precisely 
how (if at all) complex carbohydrate, glycolipid, or phospholipid antigens are 
processed by APCs remains to be determined. Clearly, this is of utmost importance 
to our understanding of immune reactions to organisms such as mycobacteria that 
contain large amounts of non-proteinaceous antigens.
Various surface glycoproteins, termed cell adhesion molecules, greatly enhance the 
efficiency of interactions between lymphocytes and other cells such as APCs, target 
cells, or endothelial cells (Springer etal., 1987) (Table 1).
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Table 1.1. Cell adhesion molecules and their ligands.
Receptor Ligand
CD2 LFA-3
CD4 MHC II
CDS MHC I
LFA-1 ICAM-I
NOTE. LFA = Lymphocyte function-associated antigen; MHC = Major histocompatibility complex; ICAM = Intercellular adhesion molecule.
1.4. Cytokines and protection of tuberculosis
Control of TB is thought to be mediated by interferon-gamma (IFN-y)-producing T 
cells (Boom et al., 1991; Conradt & Kaufinann, 1995; Cooper & Flynn, 1995; Flynn 
et al., 1993; Orme, 1988; Orme et al., 1994; Orme et al., 1993; Wallis & Ellner,
1994). Knockout mice that cannot produce IFN-y or that cannot express the IFN-y 
receptors are more susceptible to the growth of M  tuberculosis than are intact wild- 
type control mice (Cooper et al., 1993; Dalton et al., 1993; Flynn et al., 1992; 
Kamijo et al., 1993; Kaufmann & Ladel, 1994). Both CD4 and CD8 T lymphocytes 
are important in controlling the growth of the tubercle bacillus. Generally, CD4 T 
cells are considered to be cytokine-producing helper T cells while CD8 cells are 
cytolytic T cells. Both populations, however, can produce cytokines. The production 
of different cytokines by CD4 cells has led to their classification as either Thl or Th2 
cells (Abbas et al., 1996; Mosmann & Coffman, 1989; O'Garra & Murphy, 1994),
Thl cells produce predominantly IL-2, tumour necrosis factor-beta (TNF-p) and 
IFN-y and these are important in the generation of cell-mediated immunity while Th2 ^
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cells have been shown to produce IL-4, IL-5, IL-6, IL-10 and other cytokines that 
promote humoral immune responses (Howard & Zwilling, 1999). A third population 
of CD4 cells, ThO cells, has been shown to produce combinations of both Thl and 
Th2 cytokines (Abbas et al., 1996; McKisic et al., 1993; Mosmann & Coffman, 
1989; O'Garra & Murphy, 1994; Pearce & Reiner, 1995; Tsukaguchi et al., 1995; 
Wang et a/., 1994).
Mycobacteria preferentially induce Thl-like responses, as reflected by the 
production of liigh titres of IFN-y and TNF-P with low or undetectable levels of IL-4 
(Mutis et al., 1993). IL-12 favours the development of Thl-like T cell responses by 
enhancing IFN-y and antagonizing IL-4 and IL-10, thereby down-regulating the Th2 
responses (Fulton et al., 1996). Patients with tuberculosis infection frequently have a 
depressed cellular and increased humoral immune response against mycobacterial 
antigens (Sanchez et al., 1994). IL-4 and IL-10 are known to inhibit significantly the 
development of delayed type hypersensitivity (DTH) responses in mice (Tonnetti et 
al., 1995). IL-10 inliibits Thl activity through macrophage deactivation and the 
blocking of IFN-y release by Thl lymphocytes (Hsu et al., 1995). IL-12 is a key 
cytokine in immune regulation, presumably by inducing commitment from ThO to 
the Thl phenotype (Lamont & Adorini, 1996), and is held to be marker of active 
disease in pulmonary tuberculosis (Taha et al., 1997).
Apart from CD4 and CDS T- cells, two additional T-cell subsets may participate in 
TB control. These are double-negative (DN) yô T-cells and DN ap T-cells 
(Kaufmann, 1993; Kaufmann & Hess, 2000; Schaible et al., 1999). Human yô T-cells
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are profoundly stimulated by phosphorylated alkyl derivatives and probably other 
phospholigands of M  tuberculosis (Kaufmann, 1993; Tanaka et ah, 1995). 
Moreover, accumulation of yô T-cells in certain TB lesions has been described. 
Perhaps most importantly, yô T-cells-deficient mice suffer from increased 
susceptibility to high inocula of M  tuberculosis. Finally, human DN aP T-cells have 
been identified which vigorously respond to mycobacterial glycolipids and lipids, 
such as the mycolic acids of M tuberculosis (Kaufmann & Hess, 2000; Stead & 
Dutt, 1988; Schaible et al., 2000). Table 1 summarizes the T-cell populations 
involved in immunity against M  tuberculosis.
Table 1.2. T-cells population involved in immunity against TB
T-cell subset Antigen recognition In vitro frmction In vivo frmction
CD4 T-cells MHC Il/peptide IFN-y, CTL Protective
CDS T-cell MHC I/peptide CTL, IFN-y Protective
yô T-cell Direct? /non-proteinaceous 
phospholigand
IFN-y, CTL Partially
Protective
DN ap T-cell CDl/(glyco) ligand IFN-y, CTL ?
Tn summary, mycobacteria predominantly induce CD4 Thl cells and CD8 cytotoxic 
T cells with a Thl-like cytokine profile of elevated IL-2 and IFN-y levels (Mutis et 
al., 1993; Cardona et al., 1999; Orme, 1999) The presence of a Th2 response or of 
type 2 cytokines IL-4 and IL-10 is associated with progressive disease (Schauf et al..
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1993), where as a Thl-type response has been linked to protective immunity. IL-4, 
IL-10, IL-13, and transforming growth factor beta comprise the quartet of defined 
macrophage deactivating cytokines (Doherty, 1995). IL-4 blocks IL-2 and IFN-y 
secretion by polyclonally stimulated human T cells (Abehsira-Amar et ah, 1992) and 
has a selective potentiating effect on the proliferation and cytokine synthesis of Th2 
clones, while IL-10 might be involved in damaging ongoing antigen driven immune 
responses rather than in the selective regulations (Del Prete et a i, 1993). Thus, IL-4 
and IL-10 could be associated with diminished resistance to infection by 
mycobacteria (Friedland et al., 1995),
1.5. Mycobacterial Gene Expression &  Regulation
1.5.1. General introduction with relevance to foreign genes
The expression of foreign proteins in recombinant organisms is influenced by many
factors. At translational level, accumulation of protein is dictated by the balance of 
peptide synthesis rate, post-translational modification and protein folding, and 
degradation by endogenous proteases (Goldberg & Goff, 1986. One factor 
potentially influencing translation rate is the codon usage of foreign genes (de Boer 
& Kastelein, 1986. Several compilations of codon usages of genes of mycobacteria 
have been published (Andersson & Sharp, 1996; Dale & Patki, 1990.; Wada et al,
1992). Although the codon bias of foreign genes expressed in mycobacteria may play 
a role in determining expression level, other factors affecting translation initiation are 
likely to be more important in influencing protein expression (Buell & Panayotatos,
1986). These include the sequence around the ribosome-binding site, the structure of 
the 5' end of the mKNA, and the sequence around the initiation codon. For the most
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part, foreign proteins can be successfully expressed in mycobacteria as fusions with a 
small portion of the 5' end of an efficiently expressed mycobacteria gene, including 
the Shine and Dalgamo sequence, initiator codon, and several codons fi-om the amino 
terminus of the fusion partner (Stover et al., 1991).
Generally genes are present at one copy per cell, and one enzyme (RNA polymerase) 
is responsible for transcribing them. Some genes are transcribed frequently, and 
others once per cell generation (Hahn et al., 1977). Transcription initiation is the 
rate-limiting step in mRNA synthesis and depends on the strength of the promoter. In 
E. coli, the -10 and -35 promoter sequences interact directly with the KNA 
polymerase and, therefore, play a central role in gene expression. There are also 
some conserved and weakly conserved sequence homologies on either side of these 
hexamers, however, which may be important in promoter function. These regions 
probably also interact with the RNA polymerase, and it is likely that the entire 60 bp 
between -50 and +10 are important for transcription. There are a number of factors 
that determine promoter strength such as the individual contribution of nucleotide 
sequence, spacer length, DNA conformation, and electrostatic binding within the 
promoter combine to establish total promoter strength (McClure, 1985).
1.5.2. Transcription & translation initiation in mycobacteria
The complete genome sequence of the well-characterized H37Rv strain of
M  tuberculosis has been determined as part of a collaborative project featuring the 
Sanger Centre and the Institut Pasteur. The genome comprises 4,411,529 bp and has 
an average G+C content of 65.6% (Cole et al., 1998). Since the G+C content of a
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genome affects codon usage and the promoter recognition sites in an organism 
(Nakayama et al., 1989; Ohama et al., 1987), it can be expected that the transcription 
and translation signals in mycobacteria may differ from those in other bacteria, such 
as E. coli. For instance, GTG is often used as a start codon in mycobacteria, as 
opposed to ATG in E. coli, and mycobacterial genes show a relatively high degree of 
codon bias, reflected by predominance of G or C at position 3, especially in 
M  tuberculosis (Andersson & Sharp, 1996; Bannantine et al., 1997; Honore et al., 
1993; Hsieh et al., 1996; Matsuo et al., 1988; Milano et al., 1996; Morris et al., 
1992; Shinnick, 1987). The upstream regions of mycobacterial genes also have a 
higher G+C content than the corresponding genes from E. coli with some exceptions 
(M tuberculosis efpA gene)(Doran et al., 1997). It has been suggested that 
mycobacteria have a low transcription rate and a low RNA content per unit DNA, 
(Harshey & Ramakrishnan, 1977) due to a low rate of transcription initiation.
1.5.3. Features of Mycobacterial Promoters
I.5.3.I. General introduction
Transcription initiation has been most widely studied in E. coli, and therefore this 
was one of the first hosts used to study mycobacterial transcription signals (Labidi et 
al., 1985; Thole et al., 1985; Young et al., 1985). In general, mycobacterial 
promoters fimction poorly in E. coli, (Das Gupta et a l, 1993; Sirakova et al, 1989) 
although there are exceptions, for example heat shock promoters (Stover et al, 
1991). Comparative studies by Kieser et a l, (1986) have shown that mycobacterial 
genes are expressed more efficiently in Streptomyces than in E. coli. Many
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mycobacterial promoters are, in fact, similar to those in Streptomyces, and are 
usually G+C rich (69-78%) (Janssen & Bibb, 1990).
I.5.3.2. Variability of 5’ untranslated leader
The transcriptional start sites of a number of mycobacterial genes have been 
determined experimentally and demonstrate that there are large variations in the 
length of the 5' untranslated leader sequences. A number of genes that encode 
mRNA lacldng 5' leader sequences have also been identified in other prokaryotes 
(Bibb et al., 1994; Janssen et al., 1993; Marczynski et al., 1995; Wu & Janssen,
1996). The mechanisms by which these mRNAs bind ribosomes and are translated 
have yet to be elucidated. In a recent review on RNA interactions during translation 
initiation, it was proposed that a downstream box might be required for translation 
initiation in the absence of a functional Shine and Dalgamo sequence. The 
downstream box is a region of 8-13 nucleotides located downstream of the 
translation initiation codon of highly expressed E. coli and bacteriophage mRNAs. 
The functional importance of these postulated downstream boxes remains to be 
proven (Sprengart & Porter, 1997). In general, the Shine and Dalgamo sequences of 
mycobacteria are located at varying distances from the translation start sites and have 
minimal complementarity to the 3' end of the mycobacterial 16S rRNA (Honore et 
al., 1993), which suggests that ribosome binding site recognition may be less 
stringent in the mycobacteria, as in Streptomyces species (Strohl, 1992).
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1.5.3,3, a  Factors
The importance of the -10 and -35 promoter sequences lies in their interaction with 
the a  factor bound to the RNA polymerase for the initiation of transcription. The 
regions of a  factors responsible for binding to the -10 and -35 sequences are 
designated 2.4 and 4.2, respectively (Lonetto et al., 1992). Bashyam et al., (1996) 
compared these domains from M. smegmatis a  factors (MysA and MysB) to those of 
S. aureofaciens (HrdB) and E. coli (RpoD). The amino acids of the 2.4 regions were 
identical in MysA and HrdB and differed from RpoD in only three out of 23 
positions, two of which are conserved amino acid substitutions. Therefore, the -10 
binding regions are nearly identical, and would be expected to bind similar consensus 
sequences. There was, however, larger variation in the -35 binding domain. MysA 
and MysB differed from each other in 18 of the 39 amino acids of the 4.2 regions, 12 
of which are non-conserved. This suggest that they probably recognize different -35 
sequences, or possibly that the -35 region is not essential for promoter activity. 
MysA and HrdB differed by two amino acids, but MysA and RpoD differed in 14 
positions, nine of which are non-conserved amino acid substitutions. There is, 
therefore, probably poor interaction between mycobacterial -35 sequences and the 
E. coli a  4.2 region. It is interesting to note that a much larger proportion of E. coli 
promoters were shown to function in mycobacteria than vice versa (Bashyam et al.,
1996).
The close identity of MysA and HrB in the 2.4 and 4.2 regions emphasizes the 
similarities in the transcriptional machinery of mycobacteria and Streptomyces 
species and explains the fact that mycobacterial promoters fimction better in
19
Chapter 1
Streptomyces than in E. coli (Kieser et ah, 1986). Mycobacteria contain multiple a 
factors, a characteristic in common with Streptomyces species (Westpheling et al., 
1985). This allows for greater transcriptional flexibility (Bashyam et al., 1996), and 
provides an efficient means of regulating gene expression in these organisms.
1.5 3.4. The -10 and -35 Regions & Distances
In E. coli, the distance between the -10 and -35 regions varies between 17 and 19 
bp. Promoters with spacing of 17 are the strongest, although those with spacing of 15 
and 20 bp retain partial activity. Spacing of less than 16 or more than 18 result in the 
conserved contact points not lying on the same face of the DNA helix (Harley & 
Reynolds, 1987). From putative mycobacterial promoters identified to date, it is 
evident that the spacing between the -10  and the -35 regions is not critical and varies 
between 9 and 24 bp. These distances can be increased even further, as demonstrated 
by Kremer et al., 1995). These authors showed that neither increasing the distance 
between the -35 and -10 regions of the M  tuberculosis 85 A antigen gene by 64 bp 
nor decreasing it by 4 bp had any effect on the activity of the promoter, although the 
presence of the -35 region was essential. Again this characteristic is also found in 
promoters (Janssen & Bibb, 1990; Strohl, 1992).
As mentioned, mycobacterial promoters can withstand sequence variations in the -35 
region as well as variable distances between the -10 and -35 regions. In fact, the -35 
region has been shown to be non-essential for the expression of some mycobacterial 
genes (Kenney & Churchward, 1996). Other prokaryotic promoters that do not 
require a -35 region have been reported (Chan & Busby, 1989; Keilty & Rosenberg,
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1987; Kumar et al., 1993; Ponnambalam et a l, 1988). These promoters usually have 
an extended -10 region. This extended -10 region may be important contact site for 
RNA polymerase, which is critical for promoter recognition and function in the 
absence of a recognizable -35 sequence (Chan & Busby, 1989; Keilty & Rosenberg,
1987). Although the -10 and -35 hexamers play an important role in promoter 
fimction, other regions of the DNA upstream of genes can play a supplementary role.
1.5 3.5. Multiple Promoters Feature
The presence of multiple promoters is a common feature of gene expression in the 
mycobacteria. Examples of mycobacterial genes that are expressed from two or more 
promoters are the M  tuberculosis recA (Movahedzadeh et a l, 1997) gene and the 
M. bovis BCG hsp60 gene (Stover et a l, 1991). Movahedzadeh et a l, (1997) 
identified two putative promoter elements upstream of the M  tuberculosis recA 
gene, only one of which was inducible by DNA damaging agents. The presence of 
two promoters may allow differential regulation of the gene in response to 
environmental conditions. Similarly, one of the M  bovis BCG hsp60 promoters is 
more responsive to stress than the others (Stover et a l, 1991). The use of multiple 
promoters therefore provides an efficient means of regulating the expression of a 
number of genes, particularly when the promoters are differentially utilized.
I.5.3.6. Promoter DNA conformation
Stover et a l, (1991) found that expression from hsp60 promoter in M  bovis BCG 
was higher when it was present on extrachromosomal vectors than when it was 
integrated into the chromosome. In fact, it was only inducible by stress in the latter
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configuration. Levin & Hatfull, (1993) found that transcription of the M  bovis BCG 
hsp60 promoter by the M  smegmatis RNA polymerase was dependent on 
supercoiling of the DNA substrate. The authors suggest that the differences in 
expression noted by Stover et aL, (1991) may therefore be explained by the 
differences in the superhelical state of the DNA, which may play a direct role in the 
regulation of gene expression (Pruss & Drlica, 1989; Pruss & Drlica, 1985 
Richardson et al., 1988; Galan & Curtiss, 1990). They suggest that DNA 
superhelicity may be required to unwind promoter regions of G+C-rich 
mycobacterial genomes. DNA supercoiling has been shown to have a direct, positive 
and negative, effect on other prokaryotic promoters (Galan & Curtiss, 1990). It can 
also affect transcription initiation indirectly by affecting the binding of ancillary 
proteins. Bacterial virulence genes that respond to stress require DNA supercoiling 
for regulation (Dorman et a l, 1990; Higgins et a l, 1990; Mekalanos, 1992). 
Environmental stimuli such as osmolarity, temperature, oxygen levels, and starvation 
affect DNA supercoiling, and pathogenic organisms may use this to respond to these 
stimuli (Galan & Curtiss, 1990).
I.5.3.7. Conserved Transcriptional Signals
Due to the slow growth and pathogenicity of M  tuberculosis, most of the promoters 
from this organism have been studied either in an M. smegmatis or M  bovis BCG 
host. These studies have provided evidence that, in general, transcription signals are 
conserved among the mycobacteria. Bashyam et al, (1996), for example, have 
demonstrated that the efficiency and specificity of transcriptional recognition is 
conserved in M  tuberculosis, M  smegmatis, and M  bovis BCG, since the promoters
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examined exhibited similar activities and utilized the same transcription start sites in 
the three hosts. They suggested, therefore, that M  smegmatis might be used as 
surrogate host, at least for studying the connotatively expressed M  tuberculosis 
genes. Although the recognition of promoter sequence appears to be conserved 
among the mycobacteria, there may be small differences in other aspects of the 
transcription machinery, particularly between that of the slow growers and that of the 
fast growers. The M  smegmatis transcription machinery was shown to use the 
M  bovis BCG hsp60 promoter in a similar manner to BCG, however; only one 
transcription start site was active in M  smegmatis (Levin & Hatfull, 1993). In 
addition, Timm et al., (1994) reported differences in the relative strengths of three 
mycobacterial promoters in M  smegmatis and M  bovis BCG. Thus the viability of 
studying M. tuberculosis promoters in other mycobacterial hosts may depend on the 
particular promoter to be examined.
I.5.3.8. Upregulation in vivo
There is some evidence for the induction of some mycobacterial genes during 
infection of macrophages. Dellagostin et al., (1995) showed that the M  leprae 
18-kDa promoter exhibits low levels of expression in BCG cell infecting 
macrophages. This is consistent with the fact that the 18-ldDa protein is a major 
antigen in natural infection, and suggests upregulation of the gene during infection. 
Similarly, Via et al., (1996) demonstrated that theM  tuberculosis mtrA promoter is 
activated upon entry into J774 macrophages. The gene encodes a response regulator, 
which may be required for adaptation of the organism to intracellular conditions. The
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signals responsible for the in vivo expression of certain mycobacterial genes have yet 
to be elucidated.
Other up-regulated gene identified is promoter sequence coding for gt'oEL2 from 
M  tuberculosis found to be upregulated by stressing conditions (Garbe et al., 1996; 
Lee & Horwitz, 1995; Monahan et al., 1994). Recently Hobson, (2000), identified 
another gene QdeR) also from M  tuberculosis that seems to be upregulated during 
infection. With availability of complete genomic sequence of M  tuberculosis (Cole 
et al, 1998), other up-regulated genes are going to be identified in the future.
1.6. BCG as vaccine
1.6.1. History of BCG
A century ago. Nocard isolated a virulent M  bovis from the milk of a tuberculous 
cow. This strain, ‘Lait Nocard % was transferred in 1901 to the Institut Pasteur, where 
in 1908 Calmette and Guerin began a series of subcultures of this organism on 
glycerol-potato-bile medium. In 1921, after 230 passages, they had Mycobacterium 
that they believed was completely harmless to animals. In the same year, after trials 
of BCG vaccine on a variety of animal models, Weill-Halle and Turpin administered 
a dose of oral BCG vaccine to neonates bom to mothers with open TB and who were 
thus at high risk of developing the disease (Calmette, 1931). It was well tolerated and 
appeared to give 90% protection. On the basis of the results of its use in infants 
between 1921 and 1924, BCG vaccine was distributed around the world for the 
prevention of tuberculosis. In 1930, a tragedy occurred in the North German city of 
Lubeck where, owing to a labelling accident, the children of that city were
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vaccinated with a virulent strain of M  tuberculosis instead of BCG; 73 infants died 
and another 135 developed tuberculosis (Brewer & Colditz, 1995). Nevertheless, 
cultures of BCG were delivered for propagation in laboratories all over the world. In 
the period from 1924 to the early 1950s, subculturing on potato or Sauton media and 
harvesting after a varying number of passages resulted in the propagation of a range 
of substrains of BCG in the various countries. Detailed discussion on BCG substrain 
differentiation (both immunological and genomic) in relation to M  tuberculosis and 
M. bovis are presented in Chapter 6.
1.6.2. Current use & efficacy of BCG
BCG is currently the only available vaccine against tuberculosis and is widely 
administered within the WHO Expanded Programme for immunization. Over 3 
billion doses of the BCG vaccine are reported to have been administered over the last 
five decades with negligible side effects. Today, about 70% of the world’s children 
now receive the BCG vaccine. It also has the same protective effect against leprosy 
and therefore is given to individuals from parts of the world where leprosy is a 
common disease (Fine, 1988). It can be administered at any time after birth, and its 
efficacy is unaffected by maternal antibodies. Successful BCG vaccination leads to 
minor lesions, local self-limiting bacterial multiplication and development of 
delayed-type hypersensitivity (DTH) against mycobacterial proteins, wliich may 
persist for 5-50 years.
It is generally agreed that BCG can protect or at least ameliorate severe forms of 
systemic TB in children, particularly meningitis (Huebner, 1996). Yet, it seems to be
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of low or no protective value in adults. This vaccine cannot (in a satisfactory way) 
prevent the most prevalent form of TB, namely reactivation of dormant TB in adults 
(Huebner, 1996). Although BCG vaccine is cheap to prepare, stable, safe, and widely 
used, its efficacy varies greatly between countries. For example, protection against 
pulmonary tuberculosis was >90% in the British Medical Research Trial, yet no 
protection was seen in a major trial in South India (Fine, 1988). Various explanations 
have been given, but still there is no widely acceptable reason(s) for the variation 
observed in the efficacy of BCG vaccination. However, it has been suggested that 
differences in the population tested (Fine & Rodrigues, 1990) or errors in analysis 
and sampling of the population may be responsible for the observed variability in 
efficacy (Clemens et al., 1983). By far, the most accepted view is that the exposure 
to environmental mycobacteria is likely to be a far more important determinant of 
vaccine efficacy than any contribution by genetic factors in either host or pathogen 
(Lowrie, 1998).
Exposure and sensitization to environmental mycobacteria (and M. tuberculosis) is 
relatively light in the UK so that declining protection probably reflects declining 
immunological memory, but it is not known if repeating the BCG vaccination would 
make a difference (Lowrie, 1999). By contrast, in South India and in other regions 
where BCG efficacy against tuberculosis is low, exposure and sensitisation to 
environmental mycobacteria is intensive. Indeed, it was the prediction that 
environmental mycobacteria might interfere with BCG that led to the siting of the 
major controlled clinical trial in South India that duly failed to show any protective 
effect (Tripathy, 1979). Even repeating BCG vaccination still had no effect in
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Malawi, which is another location where there is extensive environmental 
sensitisation and the vaccine fails (Fine & Smith, 1996). It is striking that 
environmental mycobacteria also appear to interfere with the efficacy of BCG 
vaccination in cattle (Fine, 1995). In addition, a more recent in-depth analysis of 
BCG vaccination concluded that BCG vaccination reduces the risk of tuberculosis 
infection by about 50% and death by 71% (Colditz et al., 1994).
Whatever the efficacy the BCG vaccines and the explanations for their variation, the 
fact remains that BCG vaccines are being used routinely in many populations with 
little evidence of their effectiveness in protecting against pulmonary tuberculosis. 
Therefore, due to this insufficient efficacy and because the vaccine interferes with 
skin test screening (thwarting discrimination between BCG vaccination and natural 
infection with M. tuberculosis), the BCG vaccination is not recommended for general 
use in many countries. In conclusion, at the time when the incidence of tuberculosis 
is rising due to AIDS and multi-drug resistance strains, the current BCG preparations 
are less than ideal vaccine because of the unpredictable nature of their protective 
efficacy in different populations.
1.6.3. Genetic differences between M tuberculosis  ^ M. bovis and 
BCG
Many explanations for the failure of BCG have been brought forward amongst which 
two are based on immunological deficits. Gene clusters have been identified which 
are absent from BCG and present inM  tuberculosis (Mahairas et al., 1996). ESAT-6 
is a secreted protein of low molecular weight (6-kDa) (Sorensen et al., 1995) and the
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responsible gene is deleted in all BCG strains, but present in virulent M  bovis and 
M  tuberculosis (Harboe et al, 1996; Mahairas et al, 1996). MOT64 is a 26-KDa 
secreted protein, which is present in M  tuberculosis, but deleted in some strains of 
BCG (Mahairas et a l, 1996). Importantly, ESAT-6 appears to be major ligand for the 
memory immune response against M. tuberculosis and circumstantial evidence 
suggests that it is a target antigen of protective immunity (Andersen et a l, 1995). 
Immunological control of TB depends on CD4+ and CD8+ T-cells. By contrast, BCG 
is primarily a stimulator of CD4+ T-cells and thus fails to stimulate optimum 
protection (Kaufinann & Hess, 1997).
1.6.4. BCG as a recombinant vaccine vector
The anti-tuberculosis vaccine BCG is a suitable candidate for a recombinant vaccine 
vehicle and has been the focus of a great deal of investigation (Aldovini & Young, 
1991; Connell a/., 1993; Stover a/., 1991).
BCG fits the criteria for an ideal recombinant vaccine quite well, especially now that 
recent advances have allowed its genetic manipulation (Jacobs et a l, 1991). BCG is 
currently the most widely used vaccine with low incidence of serious complications 
(case fatality rate 0.19/10"^) (Valenzuela et a l, 1982). Given as a single inoculum, it 
can sensitise for 5-50 years to tuberculoproteins and it costs about $0.06 per dpse. 
Furthermore, BCG is a potent adjuvant in animals and humans and is one of the most 
heat-stable vaccines, not requiring an elaborate method of storage for maintenance of 
efficacy. The mechanism of protection against mycobacterial infections has been 
thoroughly studied and involves a complex interaction of T cell subsets (De Libero et
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al., 1988; Kaufinann & Hess, 2000; Schaible et al., 1999). BCG possesses intrinsic 
adjuvant properties, especially for the development of cell-mediated immunity, 
which has led to the use of BCG as a heterologous antigen delivery system (Stover et 
al., 1991).
Vectors have been developed that express protein antigens from bacterial and viral 
pathogens, intracellularly, extracellularly, or as lipoproteins, attached to the cell 
surface. Both cellular and humoral immune responses against a number of 
heterologous antigens have been observed in mice after vaccination with 
recombinant BCG. Some of these responses were shown to provide protection 
against challenge with the corresponding pathogen (Connell et al., 1993; 
Langermann et al., 1994; Langermann et al., 1994). There are, however, a few 
negative aspects to the development of BCG as a recombinant vaccine, such as the 
organism’s slow growth, and the induction of persistent tuberculin positivity in 
vaccinated individuals.
Introduction of recombinant-DNA (rDNA) in the mycobacteria was first achieved by 
a protoplast transformation procedure (and later by high-efficiency electroporation 
protocol) giving >10  ^ transformants per microgram of plasmid DNA in the 
appropriate host (Lugosi et al., 1989; Snapper et al., 1988; Snapper et al., 1990). 
Methods for the genetic manipulation of mycobacteria have been developed (Jacobs 
e ta l, 1991).
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To maintain plasmids in BCG carrying rDNA when mycobacteria are grown in 
animals or macrophages, Nakayama, (1988) developed an elegant system in 
Salmonella. Diaminopimelate (DAP) is a unique component of the rigid layer of the 
bacterial cell wall. Auxotrophic mutants lacking the capability to synthesize DAP 
require an external source of this important nutrient to be able to synthesize their cell 
wall structure. Without DAP, bacteria would start the synthesis of macromolecule, 
but because they would be unable to complete the synthesis of the cell wall, the cell 
would readily lyse, a process known as ‘dapless death’. However, these auxotrophic 
mutants can be complemented with a plasmid carrying a wild-type complementing 
gene.
The survival of the host cell is dependent on the maintenance of the complementing 
plasmid, and this ensures the maintenance of the recombinant antigen gene(s). Target 
genes for mutagenesis can be selected from any of the genes involved in the DAP 
pathway. In this regard, the asd genes coding for the aspartate-semialdehyde 
dehydrogenase have been the target of choice, since a mutation in the asd gene not 
only inactivates the first steps in DAP biosynthesis, but also in the synthesis of 
isoleucine, lysine, methionine, and threonine, imposing a multiple auxotrophy and a 
strong selective pressure. Mycobacteria also have DAP in the peptidoglycan layer of 
their cell walls. The BCG asd gene has been isolated and work is ongoing to generate 
strains of M  smegmatis and BCG with chromosomal deletions of the asd genes 
(Cirillo etal., 1991; Cirillo etal., 1994; Jacobs etal., 1991).
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Improved vector systems to express foreign antigens in recombinant BCG vaccines 
have been developed (Stover et al., 1991). These vectors carry the hsp60 expression 
signal to direct foreign-gene expression. This choice of promoter was made because 
it was shown to promote high-level expression of heat-shock proteins in response to 
the stress of the intracellular environment.
The E. coli P-galactosidase was one of the first antigens expressed in mycobacteria 
(Barietta et ah, 1990). Expression of {3-galactosidase from the heat-shock promoters 
reached a high level estimated at 10% of the total BCG protein (Stover et al., 1991). 
Antibody to P-galactosidase and cytotoxic T lymphocyte responses were observed in 
mice immunized with the appropriate recombinant strain. Humoral response was 
found to continue at least 16 weeks after immunization. A variety of antigens (i.e., 
viral, parasitic, and bacterial antigens) have been expressed in BCG including the 
HlV-1 gp 120 glycoprotein (Stover a/., 1991).
Recombinant-BCG vaccine vehicles can induce immune responses to foreign 
proteins produced by the bacillus, indicating that BCG can act simultaneously as an 
adjuvant and as a vehicle to produce and deliver selected antigens to the immune 
system (Aldovini & Young, 1991). The ability to engineer BCG to produce one or 
more foreign pathogen antigens has several advantages over mixtures of 
mycobacterial adjuvant and pathogen antigens. Because the antigen continues to be 
produced by BCG replicating in vivo, a BCG recombinant may provide a more long- 
lived immune response to the pathogen of interest than that provided by the simple 
mixture of BCG and antigen. It may be more cost-effective to engineer BCG
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recombinants than to produce the mixture. Perhaps most importantly, the ease with 
which bacteria can be manipulated genetically makes it possible that features of the 
BCG vaccine vehicle can be tailored to maximise the desired immune responses.
1.7. Introduction to this study
1.7.1. BCG as delivery vehicle
BCG vaccine holds the paradoxical position of simultaneously being the most widely 
used as well as the most controversial vaccine today (Fine, 1998; Bloom & Fine, 
1994). The failure of other candidate vaccines against TB in animal studies has led to 
the proposal that the existing BCG vaccine should be modified by overexpression of 
promising antigens to develop a more potent vaccine against TB. As facultative 
intracellular pathogens, mycobacteria are particularly well suited to eliciting cell- 
mediated immunity and not humoral responses.
The expression of foreign antigens from BCG is currently undergoing rapid 
expansion and intense study. A multitude of different viral, parasitic and bacterial 
antigens, including toxins, have been successfrilly expressed in rBCG. Appropriate 
rBCG vaccines can also specifically activate all the major components of the cellular 
immune system, including delayed hypersensitivity, T-cell proliferation, Thl 
cytoldne production and major histocompatibility complex class I-restricted 
cytotoxic-T-cell responses. In addition to inducing a cellular immune response, 
recombinant BCG can also induce significant levels of antibodies against foreign 
antigens (Kremer et al., 1996).
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Complete protection against pathogen challenge has been achieved with rBCG in 
some cases, including leishmaniasis and pneumococcal infection, with partial- 
protection in other cases, such as simian immunodeficiency virus and measles, and 
no protection in others, for example malaria and leprosy. The specific immunogen, 
route of vaccine administration and manner in which the foreign antigen is expressed 
all play major roles in eliciting quantitatively and qualitatively distinct immune 
responses. Already the first rBCG vaccine has been tested in human trial with a 
safety profile comparable to that of licensed BCG, thus it did not elicit immune 
responses to the vectored antigen (Edelman et al., 1999).
An important dictate from studies using the rBCG approach states that for optimal 
exploitation, different antigens will have to be expressed at different compartments 
for elicitation of optimal immune response in the case of every antigen (Stover et al., 
1991). Most previous studies using the rBCG approach for expression of viral and 
bacterial antigens were limited by the choice of mycobacterial expression signals and 
had employed the hsp60 promoter. However, the expression obtained using this 
promoter did not always result in an optimal immune activation. Hence, these studies 
suffered from the lack of an expression system that would allow a range of 
expression levels for any antigen. In systematic approach towards this goal, 
DasGupta et al., (1998) has developed a vector system for expression of various 
genes inM  bovis BCG at different levels.
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1.7.2. An approach to designing rBCG for optimal immune response
Although many foreign proteins expressed cytoplasmically in rBCG have been
shown to lead to effective humoral and cellular immunity, several proteins are only 
effective immunogens when secreted outside the BCG bacterium. Therefore, in this 
study plasmid constructs have been developed that enable foreign antigens to be 
expressed cytoplasmically, as membrane-associated lipoproteins or secreted outside 
rBCG as native proteins. Since some promoters are upregulated in vivo, these 
plasmid constructions were made using combination of different promoters and 
signal sequences in order to empirically examine the optimum immune response.
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1.8. Aim of this study
Therefore, the main aim of this research project was to investigate the effect of 
different modes of expression on immune response. In pursuing that the following 
experiments were carried out:
• Various expression systems based on combination of different promoters and 
signal sequences have been designed. Thus, enabling the expression of three 
different patterns on plasmid based system: intracellular, membranous, and 
secretory.
• Since p-lactamase is a secretory protein and readily detectable using 
nitrocefin as substrate, a pivotal trial using p-lactamase as a reporter gene was 
designed in order to evaluate the strength of the various promoters and signal 
sequences.
• Gene coding for diphtheria toxin fragment B antigen of C. diphtheriae was 
used as a foreign gene for expression. This gene was successfrilly cloned and 
expressed in BCG using a combination of various promoters and signal 
sequences. The expression was evaluated by means of immunoblotting.
Verification, quantification, and the deletional effect of foreign gene under 
control of hsp60 promoter on extrachromosomal plasmid were carried out in 
three commonly used BCG substrains.
35
Chapter 2 
General Materials & Methods
Chapter 2
2.0. Materials
Reagents and kits used in this study are listed below under the various suppliers.
Advanced Biotechnologies L td , UK 
Red hot thermostable DNA polymerase.
Amersharn International pic., UK
Hybond™-C Supper nitrocellulose membranes; Rainbow™ coloured protein 
molecular weight markers; Stravidin-peroxidase conjugate; Bovine Serum Albumin 
(BSA).
BDH Chemical Ltd.
Ammonium acetate; Calcium chloride; Glucose; Magnesium chloride; Magnesium 
sulphate; Phenol; Sodium carbonate; Sodium dihydrogen orthophosphate dihydrate; 
Disodium hydrogen orthophosphate; Sodium acetate anhydrous; Tween 80.
Bio-Rad Laboratories L td , UK 
Protein Assay Kits (cat # 500-0002).
Boerhinger Mannhein L td, UK
Taq DNA polymerase; Ultrapure PCR nucleotide mix; Cal intestine alkaline 
phosphatase (CIP); restriction enzymes and buffers; Ultrapure agarose; BM
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Chemiluminescence Blotting Substrate POD for detection of proteins (Western 
blotting).
Clontech Laboratofies Inc,, USA 
Advantage™ PCR-Pure Kit (cat# 1111-1/2).
Difco
Bacto Middlebrook 7H9 (dehydrated); Bacto Middlebrook 7H11 agar (dehydrated); 
Middlebrook GADC enrichment.
Fison Scientific Equipment
Absolute alcohol; Acetic acid; Chloroform; Glycerol; Hydrochloric acid; Methanol; 
Sodium hydroxide; Sodium chloride; tri-sodium citrate.
Genosys
Custom made oligonucleotides.
Gibco-BRL 
T4 DNA ligase.
UYBAID 
Ribolysing tubes.
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National Diagnostics
Protogel™ (30% acrylamide and 0.8% bisacryylamide stock solution [37:5:1]).
New England Biolabs 
Restriction enzymes and buffers.
Oxoid
Bacteriological agar No.l; Nutrient broth No.2; Tryptone; Yeast extract; General 
ingredients for media preparation.
QIAGEN
Plasmid DNA miniprep kit.
Sigma
All chemicals unless otherwise stated.
Ultra-Violet Products Ltd
Gel Documentation System (GDS).
Whatman Laboratories L td
Whatman 3 MM filter paper.
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2.1. Bacterial strains used
Strains Remarks Source/Reference
E. coli DH5a A recombination deficient suppressing 
strain used for plating and growth of 
plasmids and eosmids
(Sambrook et al., 1989)
M. smegmatis mc^ 155 Efficient plasmid transformation mutant 
of me^ 6
(Snapper et al., 1988)
M  ÔOVW BCG Pasteur Vaccine strain ATCC # 35748
M. bovis BCG Tokyo A laboratory collection
M. bovis BCG Moreau A laboratoiy collection
2.2. Recipes and protocols
2.2.1. Culture media
Luria-Bertani Broth: lOg/1 Bacto tryptone, 5g/l yeast extract, lOg/1 NaCl, pH 7.
Luria-Bertani Agar: As LB broth with bacteriological agar 1.5% (w/v).
SOC: 20g/l Bacto tryptone, 5g/l yeast extract, 0.5g/l NaCl, KCl 2.5mM, MgSO^ 
20mM, sterile glucose 20mM and MgCl2 lOmM were added prior after autoclaving.
Nutrient Broth No,2: 25g of dehydrated NB No.2, 0.2% (v/v) glycerol, 0.05% (v/v) 
Tween 80.
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Nutrient Agar No,2: As NB No.2 without Tween 80 and with bacteriological agar 
1.5% (w/v).
Middlebrook 7H9: 4.7g of dehydrated 7H9 formula in 900ml of distilled water 
containing 0.2% (v/v) glycerol and 0.05% (v/v) Tween 80. OADC (Oleic acid, 
Albumin, Dextrose, Catalase) enrichment was added to 10% (v/v) after autoclaving.
Middlebrook 7H11: 21 g of dehydrated 7H11 formula in 900ml of distilled water 
containing 0.2% (v/v) glycerol, dissolved by heating and autoclaved. OADC 
enrichment was added to 10% (v/v) to melted media cooled to 55 °C.
All culture media were prepared using distilled water and autoclaved at 121 ®C for 
15 minutes. The appropriate concentrations of antibiotics were added whenever 
applicable. Usually, 100 pg/ml of ampicillin or 50 pg/ml of kanamycin were used to 
culture E. coli transformants and 25 pg/ml of kanamycin for mycobacterial 
transformants. Antibiotics were filter sterilised and stored at 4 °C.
2.2.2. General buffers and solutions
Phosphate Buffered Saline: 137 mM NaCl, 2.7mMKCl, 4.3mM NagHPO^, 1.4mM 
KH2PO4, pH 7.3.
Tris^EDTA (TE) pH  8: lOmM tris-HCl pH 8, ImM EDTA.
Im M  Hepes pH  8
41
Chapter 2
2.2.3. Polymerase Chain Reaction
PCR amplification was performed using the Perkin Elmer GeneAmp thermal cyclers. 
A standard reaction contained 0.25 mM of each dNTP (dATP, dOTP, dCTP, dTTP), 
100 pmol of each oligonucleaotide primer, 1 ng of DNA template and lU of Taq 
DNA polymerase in Ix PCR buffer. Typical PCR reaction conditions consisted of an 
initial dénaturation step at 95 ®C for 5 minutes, followed by 30 cycles of 
amplification with primer annealing at 58 °C for 1 minute, extension at 72 °C for 1 
minute and dénaturation at 95 °C for 1 minute. The final cycle was extension at 
72 °C for 10 minutes.
2.2.4. Small scale prepration of plasmid DNA (Alkaline lysis)
Solution I  -  Resuspension buffer 50 mM glucose, 25 mM Tris-HCI pH 8, lOmM 
EDTA, pH 8
Solution 11—Bacterial lysis solution 0.2 M NaOH, 1% (w/v) SDS, prepare fresh
Solution III -  Neutralising solution 60% (v/v) 5 M potassium acetate, 11.5% (v/v) 
glacial acetic acid, pH 4.8
Solution I V -  Elution solution 50 mM Tris-HCI, lOOmM sodium acetate, pH 8
Plasmid DNA was routinely extracted from E. coli by alkaline lysis. A 3 ml 
overnight culture (16-18 hours) was centrifuged at 10,000 g for 2 minutes and the 
supernatant discarded. The remaining pellet was resuspended in 100 pi of solution I 
and mixed briefly mixed by vortexing followed by addition of 200 pi of freshly 
prepared solution n. The contents were mixed by inversion and placed on ice for 5 
minutes. Gentle mixing and incubation followed subsequent addition of 150 pi of
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solution III on ice for 5 minutes. The mixture was centrifuged at 10,000 g for 5 
minutes to remove precipitate. The supernatant containing crude plasmid DNA was 
transferred into a microcentrifiige tube and 2.5x volume of cold (-20 ®C) absolute 
ethanol was added. This was gently mixed, incubated on ice for 5 minutes and 
centrifuged for 5 minutes. The supernatant was carefully discarded, the DNA pellet 
resuspended in 50 pi of solution IV containing 100 pg/ml RNAse and incubated at 
37 °C for 20 minutes.
2.2.5. Phenol/Chloroform extraction of DNA
Phenol:chloroform and DNA solution were mixed in equal volumes. The aqueous 
and organic phase were separated by centrifiigation at 10,000 g for 5 minutes. The 
upper aqueous layer containing the DNA was transferred to a new tube and mixed 
with an equal volume of chloroform. After another centrifugation step, the upper 
phase was retained.
2.2.6. DNA precipitation
To a given volume of DNA solution, 0.1 volume of 3 M Sodium acetate and 2.5 
volumes of 100% ethanol were added. Samples were placed at -20 overnight and 
centrifuged at 10,000 g for 30 minutes at 4 °C. The supernatant was discarded and 
the DNA pellet was washed with 1 ml of 70% (v/v) ethanol. The resulting pellet was 
air dried and resuspended in an appropriate volume of TE or water.
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2.2.7. Quantification of nucleic acids in aqueous solution
The concentration and purity of nucleic acids in aqueous solutions were determined 
by spectophotometry at the wavelength of 260 and 280 nm. A pure solution of DNA 
has a peak absorbance at 260 nm and a 260:280 nm ratio of 1.8 (Sambrook et al., 
1989). The concentration of nucleic acid was calculated according to the relationship 
of A26o^1 is equivalent to 50 pg/ml of double stranded DNA or 33 pg/ml of 
oligonucleotide.
Whenever accuracy was not required, a visual comparative intensity method was 
used. The DNA sample was electrophoresed on an agarose gel containing eithidium 
bromide adjacent to a known amount of a DNA molecular size marker. The quantity 
of DNA in the sample was estimated by comparison of the intensity of fluorescence 
of the DNA band of interest with that of an appropriate marker band of a similar size.
2.2.8. Agarose gel electrophoresis
50 X  TAE buffer 242g/l Tris-acetate, 57.1ml/l glacial acetic acid, 
lOOml/1 0.5 M EDTA.
6x Gel-loading buffer type III 0.25% Bromophenol blue (w/v), 0.25% xylene
Eithidium bromide 10 mg/ml water
Agarose gel 1% Ig/lOOml IxTAE
Gels of appropriate concentration (w/v) were prepared in Ix TAE and subjected to 
electrophoresis at 5-10 V/cm in a horizontal submarine gel tank with samples loaded 
in Ix loading buffer. Gels were then stained in an eithidium bromide bath (0.5 pg/ml
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in Ix TAE). DNA was observed using and ultra-violet transilluminator and 
photographed on a gel documentation system (UVP Imagestore).
2.2,9. DNA extraction from gels & purification of DNA from solution
Specific DNA fragment was excised from agarose gels under UV transillumination
and purified using the Advantage™ PCR-Pure BIND Kit according to the 
manufacturer’s instructions. The gel slice was weighed to estimate the volume 
(Ig = 1ml). For TAE-buffered gels, SALT™ solution was added to 3x the volume 
of the gel slice followed by incubation at 55 for 5-10 minutes. Occasionally, the 
tube was inverted or gently flicked to mix the contents and promote melting. 
Incubation was prolonged until the agarose was completely liquefied. A minimum of 
5 pi PCR-Pure BIND™ was added to the suspension, which was incubated for 5 
minutes at room temperature with occasional shaking of the tube. The suspension 
was then centrifuged at 10,000 g for 5 seconds and the supernatant discarded. The 
pellet was washed once with 1 ml of WASH™ solution and centrifijged at 10,000 g 
for 5 seconds followed by complete removal of the WASH™ solution. The pellet 
was dried at 37 °C and resuspended in water or TE buffer equivalent to 2x the 
volume of BIND™ added previously. After incubation at room temperature for at 
least 5 minutes to elute the DNA, the suspension was centrifliged at 10,000 g for 1 
minute. The supernatant was transferred to a new tube, centrifuged again to remove 
any residual BIND™, and the yield of purified DNA assessed by agarose gel 
electrophoresis.
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Purification of DNA fi’om solution was preformed in a similar manner. The DNA 
concentration was estimated and three volumes of SALT™ were added to the DNA 
solution and mixed well. Subsequent steps were as described above.
2.2.10. Restriction endonuclease digestion of DNA
Digestion of DNA was performed using the required restriction enzymes in the 
appropriate Ix restriction buffer followed by incubation at the optimum temperature 
recommended. The total reaction volume was altered according to the amount of 
DNA to be cut. The digestion products were then analysed by agarose gel,
2.2.11. Dephosphorylation of DNA
DNA was dephosphorylated using 1 unit of calf intestinal phosphatase (CIP) in the 
supplied buffer diluted to Ix, with subsequent incubation at 37 °C for 30 minutes. 
Another 1 unit of CIP was added and incubated for further 30 minutes. The reaction 
was terminated by inactivation of the enzyme at 75 °C for 15 minutes.
2.2.12. Ligation of DNA fragments
DNA fragments were ligated in a 3:1 molar ratio of insert DNA to vector using T4 
DNA ligase in the supplied Ix buffer. The reaction mixture was incubated at room 
temperature for 1 hour.
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2.2.13, Preparation of E, coli DHSa competent cells
Prepared according to the laboratory protocol by Sue Wall, Microbiology Genetic 
Group.
2.2.14, Transformation of E, coli DHSa
One pi of ligation products was added directly to 20 pi of E. coli DH5a competent 
cells. As a positive control, 1 ng of plasmid DNA was used. After gentle mixing, the 
cells were incubacted on ice for 30 minutes, heat-shocked for 45 seconds in a 42 
water bath, and placed on ice for 2 minutes. Recovery of cells was achieved by the 
addition of 180 pi SOC and incubation at 37 ®C with shaking for 1 hour prior to 
selection of transformants on LB agar supplemented with the appropriate antibiotics.
2.2.15, Preparation of mycobacterial competent cells
The M  smegmatis mc2 155 cells were grown in 50 ml of Nutrient Broth No.2 
shaking at 225 rpm for 2 days at 37 °C. M  bovis BCG was grown for 10 days in 
tissue flasks containing 100 ml of Middlebrook 7H9 supplemented with OADC at 
37 °C stationary. Cultures were chilled on ice for 30 minutes and harvested by 
centrifugation at 3,000 rpm for 10 minutes at 4 °C. The pellet was resuspended and 
washed in 25 ml of ice-cold 1 mM Hepes pH 7.4, centrifuged and washed once more 
in 25 ml of cold 10% (v/v) glycerol. Finally, the pellet was resuspended in 2 ml of 
10% glycerol and aliquots stored at -80 ®C (Snapper et al., 1990).
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A recent alternative protocol was also used for M  bovis BCG. The primary 
difference between the two protocols was the temperature at which competent cells 
were prepared and electroporated. Cells were harvested by centrifugation at room 
temperature while washed with 37 ®C warm 1 mM Hepes and 10% glycerol as 
above. A 0.2 ml of resuspended cells were mixed with 50-100 ng of DNA and placed 
in a 0.2 cm cuvette (Wards & Collins, 1996). Electroporation, recovery and selection 
of transformants were done as described bellow.
2.2.16. Transformation of mycobacteria
The required amount of competent mycobacterial cells was thawed on ice. Prior to 
use, the cells were washed in 10% (v/v) glycerol at 4 °C and resuspended in the same 
volume of ice cold 10% glycerol. For each transformation, 100 pi aliquots of 
competent cells were elctroporated with 50-100 ng of DNA in 0.2 cm electroporation 
cuvettes, using the BioRad GenePulser set at 2.5 kV, capacitance 25 pFD and 
resistance 600 O. M  stnegtnatis mc^ 155 were recovered in 900 pi of Nutrient Broth 
No.2 at 37 °C for 2 hours before plating out on Nutrient agar containing 25 pg/ml of 
kanamycin. Colonies of antibiotic resistant transformants were visible after 3 to 4 
days of incubation at 37 °C. For recovery of M. bovis BCG, Middlebrook 7H9 
medium supplemented with OADC was used and cells were incubated overnight in a 
shaker incubator. Transformants were selected on Middlebrook 7H11 containing 25 
pg/ml of kanamycin. Colonies were obtained after 3 to 4 weeks of incubation at 
37 °C. Positive colonies were then isolated and screened for possession and integrity 
of the plasmid.
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2.2.17. SDS-PAGE and western blotting 
Sample preparation
Mycobacterial cells were grown to stationary phase before harvesting the cells and 
resuspension of pellet with 1 ml of sterile water. The cell suspension was mixed with 
glass beads in a ribolyser tube and disturbed by vigorous agitation at speed of 6 for 
45 seconds in the Ribolyser™. The lysate were then centrifuged at 10,000 g for 10 
minutes. Protein samples were diluted twofold in 2x loading buffer, boiled for 5 
minutes and the requh ed amount loaded onto polyacrylamide gels.
Denaturing discontinuous polycrylamide gel electrophoresis
2x Loading buffer 75 mM Tris-HCI pH 6.8, 5% Mercaptoethanol, 
2% SDS, 10% glycerol, 0.1% Bromophenol Blue
4x Separating gel buffer, pH  8.8 1.5 M Tris-HCI pH 8.8, 0.4% (w/v) SDS
4x Stacking gel buffer, pH  6.8 0.5 M Tris-HCI pH 6.8, 0.4% (w/v) SDS
5x Running buffer, pH  8.3 125 mM Tris base, 1.25 M glycine, 0.5% SDS 
pH 8.3
Coomassie Brilliant Blue stain 0.15 g Brilliant Blue G, 25 ml methanol, 5 ml 
acetic acid, 70 ml water
Destaining buffer 10% acetic acid, 30% methanol
SDS-PAGE gels were cast using a Bio-Rad mini gel system (Mini-PROTEAN II 
dual slab cell). Polyacrylamide separating and stacking gels were prepared according 
to the recipes in (Sambrook et al., 1989). Usually, a concentration of 7.5% for the 
stacking gel, which has an effective range of separation of 36-94 kDa, and 5% for the 
stacking gel were used. The total amount of protein loaded in each well ranged from 
25 pg to 50 pg and electrophoresis was carried out at 180V until the tracking dye
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dye reached the lower edge of the gel. Whenever appropriate, gels were stained with 
Coomassie Brilliant Blue.
Transfer o f protein onto nitrocellulose membranes
Transfer buffer pH  8.3 39 mM glycine, 48 mM Tris base, 20% 
Methanol
Ponceau S stain 2 g Ponceau S, 30 g Trichloroacetic acid, 
30 g sulfosalicylic, water to 100 ml
Membrane blocking solution 3% BSA in Ix TBS
lOx Tri buffered saline (TBS) pH  7.6 2 mM Tris-HCI pH 7.6, 137 mM NaCl
TBS-Tween TBS plus 0.1% Tween-20
Following the gel electrophoresis, nitrocellulose membrane and two sheets of 
Bio-Rad extra-thick filter paper were soaked in transfer buffer for 10 minutes. 
Transfer was carried out using a Semi-Dry™ blotter (Bio-Rad). A “sandwich” of 
filter papers, nitrocellulose membrane and gel was assembled and transfer progressed 
at lOV for 30 minutes. Blotted membranes were stained with Ponceau S which is a 
transient and washable dye used to detect total protein transfer.
Immunoblotting
The nitrocellulose membrane was incubated in blocking solution for 1 hour at room 
temperature with agitation, after which a suitable dilution of primary antibody in 
0.3% BSA in TBS-Tween was added. Incubation continued for a fiirther hour. The 
membrane was washed 3x 10 minutes in TBS-Tween. A suitable dilution of 
peroxidase-conjugated secondary antibody in 0.3% BSA in TBS-Tween was added 
to the membrane and incubated for further 45 minutes. The membrane was washed
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3x 10 minutes in TBS-Tween before being subjected to the chemiluminescent 
detection according to the manufacturer’s instruction. Premixed detection reagent 
was added and incubated for up to 5 minutes. Excess reagent was drained off and the 
blot was wrapped in Saran Wrap. X-ray film was exposed for 5 seconds to 10 
minutes.
Determination o f protein concentration
Total protein present in mycobacteria cell-free extracts was assessed using the 
Bio-Rad protein assay. The test is based on the differential colour change of a dye in 
response to various concentrations of protein. Beer’s law was applied for accurate 
quantification of protein by selecting an appropriate ratio of dye volume to sample 
concentration that gave a linear extinction coefficient of the dye-protein complex 
solution over a wide range of concentrations.
A standard curve was prepared for each assay. For this purpose, serial dilutions of 
the protein standard containing 1 to 25 pg/ml were prepared. A 0.8 ml of standards, 
appropriately diluted samples and sample buffer (“blank”) were placed in test tubes 
to which 0.2 ml of Dye reagent Concentrate was subsequently added. Samples were 
vortexed, avoiding excess foaming. OD595 was measured versus reagent blank
within the period of one hour. The standard curve was plotted and the unknown 
protein concentrations determined.
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2.2.18. Automated DNA sequencing
DNA was sequenced on a Perkin Elmer Applied Biosystem 3 73A automated 
sequencer using the dye terminator cycle sequencing method (Microbiology Genetics 
Group). A minimum of 800 ng of purified DNA product was used. In general, both 
coding and complementry strands were sequenced with sense and anti-sense primer 
(4 pmol each) respectively.
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Construction of expression vectors
Chapter 3
3.0 Introduction
Bacteria and viruses are two main expression systems, which have proved to be 
potential candidates for a recombinant vaccine vehicle. Bacteria such as E, coli are 
highly efficient in expressing foreign proteins, but they are often in the form of 
insoluble inclusion bodies. Other bacteria such as Salmonella strains have been 
shown (Newton et al., 1989) to elicit humoral and cellular immune responses to an 
expressed antigen. One problem with using gram-negative bacteria as expression 
systems is the risk that the end product may be contaminated with endotoxin. Viral 
vectors may be more appropriate when glycosylation and posttranslational 
processing of the antigens are essential for the correct epitope. In the case of a live 
viral vector, initial experiments have been done with a vaccinia virus (Mackett et al., 
1982; Panicali & Paoletti, 1982). This virus is widely used because it is capable of 
generating cellular immune responses, especially those involving the cytotoxic T 
lymphocyte. However, recombinant vaccinia has produced adverse effects in 
vaccinated individuals, particularly children, and it often generates a somewhat weak 
immune response in primates (Moss, 1992).
However, there are many distinct advantages to using BCG as recombinant vaccine 
over these vectors for practical use. BCG is one of the strongest adjuvants known, 
has been used in approximately 3 billion people world-wide with negligible 
incidence of serious side-effect, immunisation elicit long-lasting immune responses, 
can be administered at birth, and the current BCG vaccines are inexpensive to 
produce. Mycobacterial products are well Imown for their efficacy as immune
54
Chapter 3
adjuvants. The activity of complete Freund's adjuvant, commonly used for 
experimental polyclonal-antibody production, for instance, relies on the presence of 
mycobacterial cell wall components. As facultative intracellular pathogens, 
mycobacteria are particularly well suited to eliciting cell-mediated immunity. Indeed, 
immune protection from mycobacterial infection has been shown to depend on the 
development of host T-helper type I responses, which are characterised by the 
elaboration of a select cytokine profile including interleukins 2 and 12, and interferon 
gamma.
Until the last decade, expression of foreign genes in mycobacteria and development 
of a recombinant BCG vaccine delivery system for heterologous antigens was never 
considered for many reasons. First, BCG had proved to be a particularly difficult 
bacterium to genetically manipulate, owing to its much longer generation time, 
resistance to many standard anti-microbial agents and DNA transformation 
efficiencies. Furthermore, because of its thick, lipid-rich cell wall, BCG will not 
form individual colonies without the addition of a detergent to the growth medium. 
Many of the prefabricated tools for bacterial genetic manipulation are also unsuitable 
for use in BCG because of its requirement for Mycobacterium-speciûc promoters, 
origins of replication and signal sequences, together with relatively high GC content 
of BCG-DN A. The construction of DNA vectors capable of shuttling between E. coli 
and mycobacteria has, coupled with the discovery of high-efficiency heat-shock 
promoters that work in both types of bacteria, greatly facilitated mycobacterial 
genetic manipulation (Aldovini & Young, 1991; Stover et a l, 1991). In general, two 
types of vectors have been utilised: an extrachromosomal plasmid or an integrating
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variant. Non-integrating plasmids have the advantage of higher copy number with 
usually higher recombinant protein expression and non-destructive alteration of the 
BCG genome.
A drawback to using resistance gene as selectable marker on plasmid based vector 
will be, the resistance gene may be transferable to other pathogenic mycobacteria or 
other bacterial pathogens. However, BCG and other infectious mycobacteria 
replicate in vivo predominantly within macrophages, so that few opportunities exist 
for rBCG to interact with other bacterial strains or species. Strains of fast-growing 
commensal mycobacteria capable of conjugal transfer of genes are apparently very 
rare, and conjugal gene transfers from slow-growing mycobacterial pathogens have 
yet to be reported (Edelman et al., 1999). In the laboratory, transfer of plasmid DNA 
into or from mycobacteria is very inefficient (Aldovini et al., 1993; Kalpana et al., 
1991). Thus the possibility that drug-resistant genes from rBCG will be transferred to 
other pathogens appears to be very remote. Nevertheless, for ultimate use as a 
vaccine, resistance genes will not be acceptable.
3.1. Optimising stability & immunogenicity of expressed 
antigens
Enzymes of the host that are capable of selectively degrading foreign proteins may 
limit expression of some foreign genes in bacteria. In many instances, it has been 
possible to stabilise expression by developing mutants in the host proteolytic
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enzymes (Goldberg & St. John, 1976); similar approaches may be useful for 
increasing stability of foreign antigens in BCG.
It has long been known that the adjuvant activity of mycobacteria resides in the cell 
wall, and it has been established that the major antigens in M  leprae and 
M  tuberculosis recognised by T helper cells reside in the cell wall as well 
(Melancon-Kaplan et al., 1988). To increase immunogenicity, particularly for 
developing antibodies, and to prevent foreign proteins from becoming toxic to BCG, 
it may be advantageous to include mycobacterial signal sequences that will permit a 
significant number of recombinant proteins to be secreted from the recombinant 
BCG vector (Stover et al., 1993). An equally compelling argument for developing 
recombinant BCG that can secrete introduced antigens is derived from the current 
immunologic paradigm that holds that to develop major histocompatibility complex 
(MHC) class I-restricted cytotoxic T lymphocytes (CTLs), it is important for the 
antigen to be present in the cytoplasm of the antigen-presenting cells and target cells 
(Moore et al., 1988). Even in those cases when a particular antigen may induce a 
positive CTL response in the absence of secretion (Stover et ah, 1991), it may be 
possible to enhance this response through secretion. Directing recombinant antigens 
to the bacterial cell wall is attractive because of the high immunogenicity of 
mycobacterial cell walls.
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3.2. Promoters and signal sequences
3.2.1. Hsp60
Heat shock proteins are produced under normal physiological conditions but their 
synthesis is markedly increased when the cells are exposed to elevated temperature 
or other stress conditions, such as oxidative free radicals. Heat shock protein 
promoters have been extensively studied as they are usually upregulated in response 
to a variety of stress conditions and control the expression of mycobacterial antigens, 
which may represent the major targets of cell-mediated immune responses 
(Kaufrnann, 1990; Lindquist & Craig, 1988).
3.2.2.18-kDa
Screening a M  leprae library? with murine monoclonal antibodies Mustafa et ah, 
(1986) originally isolated the 18-kDa antigen. Unfortunately in vitro transcription 
from the 18-kDa promoter is lower than that for other promoters commonly used in 
mycobacterial expression systems (Dellagostin et al, 1995). However the same 
studies suggest that the incubation of mycobacteria harbouring an 18-kDa: :/acZ gene 
fusion in cultured murine J774 macrophages significantly increased levels of the
18-kDa: :B-glactosidase reporter protein. Therefore, recombinant mycobacterial 
vaccines in which the 18-kDa promoter drives production of target antigens may 
target the production of heterologous proteins to antigen presenting cells.
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3.2.3.19-liDa
The 19-lcDa protein was originally identified as a major antigen of M  tuberculosis 
on the basis of its recognition by murine monoclonal antibodies raised against crude 
bacterial extracts (Engers et al., 1986). Subsequently, this antigen was shown to be 
the target of both antibody and T cell responses in the course of tuberculosis 
infection and BCG vaccination in humans (Faith et al., 1991; Harris et al., 1993; 
Jackett et al, 1988). In addition to acylation, there is evidence of glycosylation with 
19-kDa antigen (Herrmann et al, 1996). The ability of lipoproteins to induce 
immune responses; particularly antibody-mediated responses; has been exploited for 
development of antigen delivery systems (Abou-Zeid et al, 1997). Expression of 
heterologous proteins as lipoproteins through the addition of signal sequence and 
acylation motif derived fi*om the 19-kDa antigen has resulted in the development of 
various recombinant BCG vaccine candidates (Stover et al, 1993; Stover et al, 
1991). High-titered protective antibody responses were induced in mice immunised 
with outer surface protein A (OspA) of B. burgdorferi expressed in rBCG as 
membrane-associated lipoprotein (Langermann et a l, 1994; Stover et al, 1993). This 
construct provided protective antibody response in mice that were 100- to 1000-fold 
higher than responses elicited by rBCG, which expressed OspA in the cytoplasm or 
as a secreted fusion protein.
Recently Zhu et a l, (1997) observed a protective effect of vaccination when the
19-kDa antigen was delivered in the form of a recombinant vaccinia construct.
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3.2.4. 85A
Proteins secreted by live BCG have attracted considerable attention in the field of 
vaccine research, since live BCG can provoke protective immunity against 
tuberculosis while killed organism cannot (Orme, 1988). It is reasoned that, since 
they are available for processing and presentation to T cells prior to release of 
cytoplasmic or cell-wall proteins from dead bacteria, they will act as key targets for 
protective immune responses at the early stages of infection (Andersen et a!., 1991; 
Orme et al., 1993). Antigen 85 complex is one of the dominant secreted antigens and 
consists of three structurally related components, Ag 85A, Ag 85B and Ag 85C. 
After infection or vaccination Ag 85 complex were able to induce strong T cell 
responses and interferon gamma secretion (Huygen et al., 1994; Launois et al., 
1994). Recently, it was shown that vaccination with components of Ag 85 could 
confer protection against challenge withM tuberculosis orM  leprae (Horwitz et ah, 
1995; Naito et al., 1999). Vaccination with DNA vectors encoding components of 
Ag 85 also conferred protection of infection ofM  tuberculosis (Huygen et al., 1996). 
Heterologous expression systems using Ag 85A antigen signals have been recently 
developed and the production and secretion of several foreign antigens by these 
systems have been demonstrated (Baulard et a l, 1996; Kremer et al, 1995).
3.3. Aim of this study
The aim of this study is to develop vector constructs, using combinations of 
promoters and signal sequences that enable foreign antigens to be expressed
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cytoplasmically, or as membrane-associated lipoproteins or secreted outside rBCG as 
native proteins.
3.4. Material and methods
All material and methods used were same as those described in Chapter 2.
3.4.1. Plasmids construction
Using pUC19 as plasmid base, a shuttle vector was generated by the addition of a 
mycobacterial origin of replication derived from plasmid pAL5000 in M  fortuitum 
and the TkPOj-drived aph gene conferring kanamycin resistance as selectable 
marker. Dr, Dellagostin, performed construction of plasmids pUS972, pUS973, 
pUS974, and pUS976. Table 3.1 lists the target genes, oligo primers and templates 
used to generate amplified PCR products which were subsequently used for cloning 
using basic molecular cloning protocols as described in Material & Methods. The 
sequence for the putative -10 and -35 regions and the distance between them, as well 
as the Shine and Dalgamo site and the start codon for various promoters and signal 
sequences is shown in Table 3.2. Schematic representation of plasmids construction 
can also be seen in Figures 3.1-3. These plasmids were used to transform E. coli 
DH5a, M  smegmatis and BCG Pasteur.
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hsp60 promoter from BCG. 0.4 kb fragment containing 
383 bp of 5’ regulatory region, plus the first 6 codons.
PUS973 hsp60
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hsp60 promoter from BCG. 0.4 kb fragment containing
383 bp of 5’ regulatory region, plus MT-19 acylation signal sequence from MTB.
hsp60p u s m MT-19
hsp60 promoter from BCG. 0.4 kb fragment containing
383 bp of 5’ regulatory region, plus 85A secretional signal sequence from MTB.
hsp60 85AS
Figure 3.1 Schematic representations of plasmids pUS973, pUS974 and pUS2004
ccMistruction. Plasmid pUS972 was used as the backbone vector and all promoters were
cloned into Kpnl site, signal sequences were cloned into BamHI site.
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18-kDa promoter from M leprae, 0.3 kb fragment containing 
266 bp of 5’ regulatory region, plus the first 6 codons.
PUS2QQQ 18-kDa f t . .
18-kDa promoter from M, leprae, 0.3 kb fragment containing
266 bp of 5’ regulatory region, plus MT-19 acylation signal sequence from MTB.
PUS2M1 MT-19
18-kDa promoter from M, leprae, 0.3 kb fragment containing
266 bp of 5’ regulatory region, plus 85A secretional signal sequence from MTB.
PUS2ÛÛZ 18-kDa■ '.Qmr __________... 85AS
Figure 3.2 Schematic rcprcscntati<ms of plasmids pUS2000, pUS2001 and pUS2002
construction. Plasmid pUS972 was used as the backbone vector and all promc^ers were
cloned into Kpnl site, signal sequences were cloned into BamHI site.
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85A promoter from M TB. 0.7 kb fragment containing
669 bp of 5’ regulatory region, plus its own secretional signal sequence from MTB.
PUS976 85AS
85A promoter from MTB. 0.5 kb fragment containing
489 bp of 5’ regulatory region, plus acylation signal sequence fromM leprae.
PU.S2QQ5 85A MT-19
MT-19 promoter from MTB. 0.5 kb fragment containing 
514 bp of 5’ regulatory region, plus its own acylation signall sequence.
PUS2006 MT-19 MT-19
Figure 3.3 Schematic representations of plasmids pUS976, pUS2005 and pUS2006
constmction. Plasmid pUS972 was used as the backbone vector and all pr<Mnoters were
cloned into Kpnl site, signal sequences were cloned into BamHI site.
66
Chapter 3
3.4.2. Construction of pUS2000, pUS2001, pUS2002 and pUS2004
A DNA fragment containing the M  leprae 18-kDa promoter region and its first six 
amino acid was PCR amplified using pUS935 DNA (Dellagostin et aï., 1993) as 
template and the primers 18-kDa-F and 18-kDa-R. The 266bp PCR product was 
double digested with Kpnl and BamHI, ligated into the Kpnl and BamHI site of 
pUS972 generating pUS2000. An 112bp fragment, corresponding to the Shine and 
Dalgamo site and the start codon of the MT-19 signal sequence was PCR amplified 
(MT-19SS-F and MT-19ss-R) using pUS974 DNA as template. This 112bp acylation 
signal was double digested by BamHI and Hindlll, cloned into pUS2000 to generate 
pUS2001. Finally the secretion signal of antigen 85A again corresponding to its 
natural Shine and Dalgarno region and the start codon was PCR amplified (85Ass-F 
and 85Ass-R) using pUS976 DNA as template. After double digestion with BamHI 
and Hindlll, the 189bp fragment was cloned into pUS2000 to create pUS2002. The 
same double digested 85A fragment was cloned into pUS973 giving rise to 
PÜS2004.
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Xbal(2)
pUS9723600bp Bam I (962)XMri(99})
KatWR
SamH 1(115nal(2) MT-19pUS20003858bp f ia » «  1(982)
P(18K)
PISkDa
iÿ n l(1 2 S 3 )
K»KR)Kan(R)
pUS20013965bppUS20003858bp
M>al(976)
&mHI(982) 
RBS 
P(18K) 
PIBkDa 
Aÿ»!(12î3)
MT-19
Bm«I(10@9)
P(18K)
PIBkDa
3 ÿ n l( l3 6 0 )
Kan(R)
pUS2002
4042bpBaMil TM(97<S)
S<diH I(I1 6 6 >
P(18K)
PIBkDa
A H  (1437)
Figure 3.4 Construction of pUS2000, pUS2001 and pUS2002. Promoter 18-kDa was 
generated by PCR and cloned into Kpnl and BamHI site of pUS972 giving rise to pUS2000. The MT-19 signal sequence was generated by PCR and clcmed into pUS2000 creating pUS2001. SccrcticHi signal 85A was amplified by PCR and inserted into pUS2000 giving rise to pUS2002.
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3.4.3. Construction of 2003, pUS2005 and pUS2006
Primers 85Ap-F and 85Ap-R were used to PCR amplify promoter 85A from pUS976 
template DNA. The resulting 489bp fragment was double digested with Kpnl and 
BamHI, cloned into pUS972 to generate pUS2003. The BamHI and Hindlll digested 
PCR product of 85A-signal sequence was cloned into pUS2003 to create pUS2005. 
Finally using primers MT-19p-Fl and MT-19p-Rl, and MTB as template 
(WWW, sanger. ac.ukl a region of 514bp up stream of MT-19 start codon was targeted 
as its promoter region and amplified along with its signal sequence. This 514bp 
fragment was double digested with Kpnl and Xbal, cloned into pUS972 creating 
pUS2006.
3.4.4. Construction of pUS2007 and testing for promoter activity
Using primers MT-19p-F2 and MT-19p-R2, and pUS2006 DNA as template, a 
fragment containing the entire MT-19 promoter region along with its acylation signal 
sequence was generated. The 519bp PCR product was double digested with Narl and 
Xbal, cloned into promoterless lacZ, E. co//-mycobacteria shuttle vector pUS1800 
(Hobson, 2000) to generate pUS2007. Both pUS1800 and pUS2007 plasmids were 
transformed into BCG and selected on plate containing kanamycin and X-gal. After 
three weeks of incubation at 37 ®C, blue colonies were observed on pUS2007 plate 
while no blue colonies were seen on pUS1800 plate. This confirmed the activity of 
MT-19 gene promoter at the region chosen for cloning.
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85A
pUS2003
4094bp Æ a l(9 7 6
8 a» H I(U 7 6 )
pUS972
3600bp t_ II P(tan)B«HU9n 
A)wd(995)
XbaH2) wr-19
K*n(R)
pUS973
3984bp
» d ( 9 7 6 )pUS2005
4187bp B anH  1(1089)
*Jw d(l582)
(^976)
—  & «>H I(9S2>  X b a l(2 )
RBS ±
PhspBO I
>Jwd<1379)
KaiKR)
3M(97<S)pUS2004
4169bp
H 1(1166)
Figure 3^ Construction of pUS2003, pUS2005 and pUS2004. Promoter 85A was generated by PCR and cloned into Xbal-BamHI site of pUS972 giving rise to pUS2003. The 
MT-19 signal sequence was generated by PCR and cloned into pUS2003 creating pUS2005. 
Secretion signal 85A was amplified by PCR and inserted into pUS973 givii% rise to pUS2004.
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pUS972
3600bp
OriM
OriE pUS2006
4100bp m i  (976)
MT-19P
T4ohM
KN(R) Afarl (35)
lacZ
pUS18007830bporiE
OhM
Xbal (16)
KN(R) pMT-19
N a rl(538)
pUS2007
8333bponE lacZ
OhM
Figure 3.6 Construction of pUS2006 and pUS2007. A 514bp regicm frcan MTB containing MT-19 promoter and its signal sequence was cloned into pUS972 Kpnl and Xbal site giving 
rise to pUS2006. The same promoter and signal sequence was amplified and cloned into pus 1800 to generate pUS2007,
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Table 3.3 Summary of shuttle plasmids used in this study
Plasmids Promoter Signal Sequence
pUS972 - -
PÜS973 hsp60 -
PÜS974 hsp60 MT-19
PUS2004 hsp60 85A
pUS2000 18-kDa -
pUS2001 18-kDa MT-19
pUS2002 18-kDa 85A
PÜS2003 85A -
PÜS976 85A 85A
PÜS2005 85A MT-19
PÜS2006 MT-19 MT-19
pUS2007 MT-19 MT-19 {lacZ as reporter gene)
The above table shows the summary of promoters and signal sequences used in this study
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3.4.5. Verifying the newly constructed vectors
All vectors were examined for its right constructs using appropriate restriction 
enzyme(s) and subsequent running on agarose gel. A single colony was chosen and 
grown for plasmid isolation as described in Chapter 2. The purified DNA was 
sequenced to confirm insert orientation. Again all vectors were transformed into both 
M  smegmatis mc  ^ 155 and BCG to examine its transformation rate and stability. 
Random colonies from transformed BCG for each of the vector were recovered back 
into E. coli and screened for integrity of fully intact plasmid.
3.5. Discussion
Studies in experimental rodents have shown that strong humoral immunity can be 
elicited, usually for months after a single inoculation (Langermann et ah, 1994; 
Stover et al., 1991). Even higher antibody titres of longer duration have been 
achieved by additional rBCG inoculations (Gheorghiu et al., 1994; Wada et al., 
1996). Appropriate rBCG vaccines can also specifically activate all the major 
components of the cellular immune system, including delayed hypersensitivity, 
T-cell proliferation, Thl cytokine production and MHC-I restricted cytotoxic-T-cell 
responses (Aldovini & Young, 1991; Fennelly et al., 1995; Honda et al, 1995; 
Stover et al, 1991; Winter et al, 1991). Live antigen-expressing rBCG appears to be 
critical for providing strong, specific, cell-mediated immunity -both dead rBCG or 
live non-recombinant BCG mixed with antigen are significantly less effective 
(Langermann gra/., 1994; Stover era/., 1991).
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The specific immunogen, route of vaccine administration and most importantly the 
manner in which foreign antigen expressed all play major roles in eliciting 
quantitatively and qualitatively distinct immune responses (Lagranderie et a l, 1997; 
Langermann era/., 1994; Stover era/., 1991).
Today most of the available expression vectors for mycobacteria rely on the 
conserved heat shock promoters of hsp60 and hsp70 genes and thus limit the range of 
expression of genes in these organisms (Aldovini & Young, 1991; Stover et a l, 
1991). Although many foreign proteins expressed cytoplasmically in rBCG have 
been shown to lead to effective humoral and cellular immunity, several proteins are 
only effective immunogens when secreted outside the BCG bacterium (Langermann 
et a l, 1994). Therefore, vector constructs were made that enable foreign antigen to 
be expressed cytoplasmically, secreted outside rBCG as native proteins or 
membrane-associated lipoproteins.
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Promoter Strength Evaluation
Chapter 4
4.0. Introduction
Techniques for studying gene expression fall in two categories: ‘genetic methods’, 
the study of gene fusions, and ‘biochemical methods’ for the detection of 
transcription (mRNA) or translation (protein) products. Here only gene fijsion will be 
considered and discussed as a promoter strength evaluation method.
4.1. Gene fusion for foreign gene expression
Gene fusion is a powerful tool for the study of gene expression. Fusions are 
constructed by creating chimeric DNAs between the gene of interest and a reporter 
gene. If the reporter gene is placed under the control of both transcriptional and 
translational signals of the target gene and a hybrid protein is produced, the construct 
is defined as a translational or gene fusion. When an intact reporter gene containing 
its own translational start signals is placed downstream from the promoter and the 
transcriptional start point of the target gene, the construct is called a transcriptional 
or operon fusion.
There are basically two ways to construct gene fusions; the first method is to modify 
a transposable genetic element to harbour a reporter gene without affecting its 
transposition functions. The second method of fusion construction is based on 
recombinant DMA. The fiision is created in vitro using a plasmid or phage that 
carries the reporter gene.
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Two precautions need to be taken when using plasmid vectors for fiision 
construction. A common problem is that readthrough from plasmid promoters 
interferes with the monitoring of target promoter activity. This problem is overcome 
in most cases though the incorporation of transcription terminators upstream of the 
reporter gene. Another possible problem is that some promoters respond differently 
when placed in a multicopy plasmid. This has been observed with the regulatory  ^
sequences of the heat-shock gene hsp60 from M  bovis BCG. An hsp-604acZ fusion 
produced P-galactosidase constitutively when placed on a plasmid, but when 
integrated into the BCG chromosome, showed an increase in p-galactosidase levels 
in response to stress with heat, acid and peroxide (Stover et ah, 1991). The reason for 
these discrepancies between extraclnomosomal and integrated fusions are not 
completely understood, but have also been observed in other organisms (Zuber et ah, 
1987).
4.2. Reporter genes used in mycobacteria
In the last decade several reporter genes have been successfully used in 
mycobacteria. Only so called 'classical reporter genes' and not the bioluminescent 
reporter genes will be discussed since the latter do not give the true quantitative 
value of expression level. These reporter genes will be mentioned with brief 
advantages, limitations and their specific applications.
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4.2.1. lacZ
This was the first and most widely used reporter gene in mycobacteria. The lacZ 
gene product, E. coli p-galactosidase, is readily detected in bacterial colonies by 
addition of the compound X-gal to the medium; colonies expressing lacZ exhibit a 
blue colour, the intensity of which provides an estimation of the levels of lacZ 
expression, p-galactosidase activity can also be quantitatively assayed in bacterial 
extracts through the colorimetric compound o-nitrophenyl-p-D-galactosidase 
(ONPG) or, by using fluorescent substrates when the levels are low or when the 
number of bacteria is reduced as is the case in infected macrophages. Both operon 
and gene fusions to lacZ are possible, enabling the study of gene regulation at the 
post-transcriptional level. lacZ fusions were also employed (Dellagostin et al., 1995) 
to study gene regulation in vivo using fluorescein-di-P-D-galactoside (FDG), which 
can cross the cell envelope of mycobacteria and mammalian cells.
4.2.2. cat
The cat gene product, chloramphenicol acetyltransferase (CAT), inactivates 
chloramphenicol, an antibiotic that is quite stable and can be used with slow and 
rapidly growing mycobacteria since both exhibit very low levels of natural 
resistance. Therefore, using cat is an alternative to lacZ provides a selectable 
phenotype. However, cat activity is reported to be low (Timm et al., 1999) when it is 
fused to another polypeptide, therefore gene fusions to cat are usually transcriptional.
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4.2.3. xylE
The gene from Pseudomonas, xylE, is another alternative to lacZ. The product of 
xylE, catechol 2,3-dioxygenase (CDO), converts catechol into a compound with a 
yellow colour, which permits the screening for colonies harbouring active 
transcriptional frisions (Konyecsni & Deretic, 1988). xylE was used to analyse the 
expression of the response regulator gene mtr from M  tuberculosis (Curcic et ah, 
1994).
4.2.4. phoA
The phoA gene product, E. coli alkaline phosphatase, functions as a reporter of 
protein export since, usually, translational fusions to a truncated phoA produce 
proteins with alkaline phosphatase activity only when the target gene encodes an 
exported protein containing a signal sequence (Hoffinan & Wright, 1985). This 
permitted the isolation of previously uncharacterised putative exported proteins from 
M  tuberculosis (Lim et al., 1995). phoA has also been employed in studies where the 
target gene encoded a known exported protein, e.g. the M  fortuitum (3- lactamase 
gene (Timm et al., 1994) and theM  tuberculosis 85A gene (Kremer et al., 1995).
4.2.5. IVET systems
This system uses the host (the cell cultures or animal) as a ‘selective medium’ to 
enrich for gene frisions that are preferentially expressed in vivo. IVET is basically a 
promoter trap in which the reporter gene encodes a protein required for pathogenesis 
or one that confers antibiotic resistance. Usually, IVET vectors contain a second
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reporter gene, which can be monitored in vivo and allows counter screening for 
fusions expressed in these conditions. A system has been developed for 
mycobacteria, which uses inhA as a reporter (Dubnau et al., 1997). This gene confers 
isoniazid (INH) resistance to M  tuberculosis when expressed on a multicopy 
plasmid. Thus, conditionally expressed promoters can be identified by selection for 
INH resistance under in vivo conditions, followed by screening for INH sensitivity 
under laboratory conditions.
The above reporter genes have been used successfully in mycobacteria either as 
transcriptional or translational fusions. The reporter genes cat and xylE are ruled out 
from use in our study since they can be used only in transcriptional fusions 
(Konyecsni & Deretic, 1988). The widely used reporter gene lacZ cannot also be 
considered since it is a cytoplasmic protein and thus cannot be secreted outside the 
mycobacteria cell. Finally, phoA produces proteins with alkaline phosphatase activity 
only when the target gene encodes an exported protein containing a signal sequence 
(Jimmet al., 1999).
4.3. Mycobacteria and P-lactamase
The low permeability of the cell envelope is usually considered to be a major factor 
in the high resistance of most mycobacteria to antimicrobial agents (Jarlier & 
Nikaido, 1990), but the production of antibiotic modifying enzymes also contributes 
to this phenomenon in both clinical and natural isolates (Zhang et al., 1992). 
Accordingly, the low sensitivity of mycobacteria to p-lactam antibiotics (Jarlier et
8 0
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a l, 1991) rests in part on the cell wall difruslon barrier and the production of 
p-lactamase. The presence of the latter enzyme has been detected in a large number 
of species such asM  smegmatis (Kasik, 1968), M  bovis (Backelin et al., 1973) and 
M  tuberculosis (Finch, 1986). However, preliminary enzyme assays with a 
homogenized sample of BCG using nitrocefin showed poor p-lactamase enzyme 
activity compared to that of E. coli containing pUC18. This, prompted us to use 
E. coli P-lactamase gene as an alternative reporter gene to evaluate promoter strength 
in BCG.
4.4. Aim of this study
The aims of the study are: (T) to develop a genetic system, based on P-lactamase as a 
reporter gene to evaluate the strength of various promoters and signal sequences; (II) 
to test the system both in different conditions of extracellular growth and during 
growth inside macrophages.
4.5. Materials & methods
All material and methods for the cloning and expression as well as the transformation 
are the same as described in Chapter 2. In this study M  bovis BCG substrain Pasteur 
(ATCC # 35748)M  smegmatis mc^ 155 and E. coli DH5a were used for expression.
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4.5.1. Methods
4.5.1.1. Plasmids construction
An 850 bp DNA fragment from pUC18 coding for the p-lactamase gene and its 
secretional sequence was PCR amplified using primers Amp-F ('5-AGTCTAGA 
TATGAGTATTCAACATTTC-3 ) and Amp-R ( '5-TGAAGCTTACCAATGCTTA 
ATCAG ). The amplified product was double digested with Xbal and Hindlll before 
being cloned into previously constructed (Chapter 3) plasmids: pUS973, pUS974, 
pUS2004, pUS2000, pUS2001, pUS2002, pUS976, pUS2005 and pUS2006 
generating: pUS2091-2099 respectively.
AH newly constructed plasmids were redigested and partially sequenced to confirm 
their construction. Summary of constructed plasmids containing the p-lactamase 
gene can be seen in Table 4.1, while schematic representations of plasmids 
construction are shown in Figure 4.1-3. AH of the newly constructed plasmids were 
then transformed by electroporation into M  smegmatis mc^ 155 and M. bovis BCG 
Pasteur.
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hsp60 promoter from BCG. 0.4 kb fragment containing 
383 bp of 5’ regulatory region, plus the first 6 codons and P-lac.
PÜS2Q91 hsp60
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hsp60 promoter from BCG. 0.4 kb fragment containing 383 bp
of 5’ regulatory region, plus MT-19 acylation signal sequence from MTB and p-lac.
hsp60 MT-19 fr iac
hsp60 promoter from BCG. 0.4 kb fragment containing 383 bp
of 5’ regulatory r^ion, plus 85A secretional signal sequence from MTB and p-lac.
hsp60 85AS..
Figure 4.1 Schematic representations of plasmids pUS2091, pUS2092 and pUS2093 
construction. Plasmid pUS972 was used as the backbcme vector and all promoters were 
clcmed into the Kpnl site, signal sequences were cloned into the BamHI site and P-lactamase was cloned into the Xbal site.
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18-kDa promoter from M, leprae, 0.3 kb fragment containing 
266 bp of 5’ regulatory region, plus the first 6 codons and P-lac.
PUS2094 18-kDa
18-kDa promoter from M leprae, 0.3 kb fragment containing 266 bp 
of 5’ regulatory region, plus MT-19 acylation signal sequence from MTB and p-lac.
PUS2095 "S' fMT-19
18-kDa promoter from M, leprae, 0.3 kb fragment containing 266 bp 
of 5’ regulatory region, plus 85A secretional signal sequence from MTB and p-lac.
PUS2096
1 j a S B s S i i
18-kDa 85AS p-lac
Figure 4.2 Schematic representations of plasmids pUS2094, pUS2095 and pUS2096 
construction. Plasmid pUS972 was used as die backbone vector and all promoters were cloned into the Kpnl site, signal sequences were cloned into the BamHI site and p-lactamase was clcmcd into the Xbal site.
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85A promoter from MTB. 0.7 kb fragment containing 669 bp of 5’ 
regulatory region, plus its own secretional signal sequence from MTB and (3-lac.
pIIS2Q97 85A p-lac
85A promoter from MTB. 0.5 kb fragment containing 489 bp
of 5’ regulatory region, plus acylation signal sequence fromM leprae and |3-lac.
PUS2098 85A MT-19
MT-19 promoter from MTB. 0.5 kb fragment containing
514 bp of 5’ regulatory region, plus its own acylation signal sequence and p-lac.
pIJS2099 MT-19 p-lacMT-19
Figure 4.3 Schematic representations of plasmids pUS2097, pUS2098 and pUS2099 
construction. Plasmid pUS972 was used as the backlxme vector and all promoters were cloned into the Kpnl site, signal sequences were cloned into the BamHI site and p-lactamase was cloned into the Xbal site.
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Table 4.1 Summary of shuttle plasmids containing p-lac gene
Plasmid Promoter Signal Sequence
pUS2090 w -
pUS2091 hsp60 -
pUS2092 hsp60 MT-19
pUS2093 hsp60 85A
pUS2094 18-kDa ”
pUS2095 18-kDa MT-19
pUS2096 18-kDa 85A
pUS2097 85A 85A
pUS2098 85A MT-19
pUS2099 MT-19 MT-19
The above table shows the list of promoter and signal sequences diiving p-lactamase gene used in this study.
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4.5.1.2. p-lactamase assay using nitrocefin
All bacteria were grown in media as described in Chapter 2. E. coli DH5a was grown 
overnight in 5 ml broth, M. smegmatis mc  ^ 155 was grown for 72 hours in 10 ml 
broth while BCG Pasteur grown for two weeks in 10 ml broth. After harvesting the 
culture by centrifugation at 3,000 g for 15 minutes, the supernatants were kept on ice 
while the pellets were washed once with sterile water and resuspended in 500 pi of 
lOOmM phosphate buffer pH 7.0. The samples were subjected to either cold 
sonication using three cycles of 30 seconds (£’. coli) or homogenized (mycobacteria) 
at speed setting 6 for three cycles of 20 seconds. All samples were kept on ice 
between brief ribolyzing. Samples were centrifuged at 13,000 g for 20 minutes in 
order to separate the membrane fraction from the soluble material containing the 
periplasmic and cytoplasmic compartments. The P-lactamase activity was assayed by 
measuring the initial rate of hydrolysis of a lOOpM solution (1 ml) of nitrocefin in 
100 mM phosphate buffer pH 7.0.
4.5.1.3. Determination of specific activity
The rate of hydrolysis of nitrocefin was measured at 486 nm with a 
spectrophotometer over the initial linear part of the hydrolysis curve. The samples
were kept at 37 between readings. The total soluble protein content of the crude 
extract and that of the supernatant were measured using a Bio-Rad assay (see 
Chapter 2). The specific activity was expressed as the amount (pmoles) of nitrocefin 
hydrolysed / min / g of protein.
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4.5.1.4. Tissue culture and infection of monolayers
The mouse macrophage cell line J-774 (ATCC # HB-197) was grown in RPMI-1640 
containing 10% foetal calf serum and 2 mM glutamine. Five millilitres of a 
suspension of cells at 5 x 10  ^ viable cells per ml were used to inoculate a 175 cm  ^
tissue culture flask containing 50 ml media, followed by 2 days incubation at 37 °C 
in 5% CO2 On the second day the media was removed and fresh media was added 
and the culture was incubated for a further day.
The mouse macrophage cell line J-774 was infected with approximately 10 bacteria 
per macrophage. After 4 hours of infection at 37 °C the cells were rinsed twice with 
Hanks balanced salt solution to remove extracellular bacilli. Rhodamin 123 (3 pg/ml) 
staining confirmed the absence of extracellular bacteria and revealed that 50%-60% 
of macrophages were infected. The number of mycobacteria per cell was similar for 
macrophages that were infected for each of the rBCG tested and varied from 10 to 
more than 30. Macrophages were incubated for 24 hours before being removed from 
the culture flask and treated with ice-cold SDS (0.0025%) to rupture the 
macrophages and release mycobacteria bacilli. The above mixture of macrophage 
and bacilli were centrifuged at 1000 g for 2 minutes to pellet the unwanted 
macrophage debris while the bacilli remained in supernatant. The supernatant was 
centrifuged for 20 minutes at 4000 g washed twice with SDS (0.0025%) and the 
centrifugation was repeated. The remaining pellet was mixed with 400ul of water, 
homogenized and nitrocefin assays were performed as described previously.
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4.6. Results
4.6.1. Strength of mycobacterial promoters & signal sequences
The P-Iactamase enzyme is a secretory protein and readily detectable using nitrocefin 
as a substrate. It was therefore chosen to evaluate the strength of the plasmid 
constructs in terms of gene expression. The promoter activity of the cloned 
p-lactamase gene in E. coli, M  smegmatis and M  bovis BCG Pasteur was 
determined by the measurement of p-lactamase activity in supernatants and cell 
extracts. The results for four separate experiments are shown in Figure 4.4.
A comparison of promoter and signal sequence activity of p-lactamase in È. coli 
shows surprisingly that all plasmid constructs were functional in expressing 
P-lactamase except for those plasmids with the 85A promoter. The level of 
p-lactamase activity was highest with the 18-kDa promoter and 85A secretory signal 
(pUS2096) in both supernatant and homogenized E. coli cells. The reason for the 
high level of P-Iactamase with this particular combination of promoter and signal 
sequence plasmid and not 18-kDa promoter alone or 18-kDa with MT-19 acylation 
signal could be due to protein degradation or instability of the p-lactamase protein 
when expressed in cytosol or as membrane-associated lipoprotein.
The rBCG supernatant assayed for P-lactamase activity showed no significant 
differences among the different constructs and BCG alone as result of four separate 
experiments (Figure 4.5) due to high level of basal p-lactamase produced fi’om native 
BCG. Although P-lactamase was produced, it might have been trapped in the 
bacterial cell periplasmic compartment. While in homogenized rBCG samples,
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unexpectedly the level of (3-lactamase activity was highest with the 85A promoter 
with its own secretional signal sequence. The next highest level of expression was 
with the 18-kDa promoter and 85A signal sequence. The results of four separate 
experiments are shown in Figure 4.5. These observations indicate that the 85A signal 
sequence may be carrying an enhancer that stimulates the binding of 
RNA-polymerase and hence transcription and translation of the reporter gene. 
However, enhancers are for the most part not folly characterized but are known to 
occur in eukaryotes, where they could be at either upstream or downstream of the 
transcriptional starting site.
Analysis of plasmid constructs recovered in E. coli from transformed BCG, showed 
that as high as a 90% deletion of the plasmid was observed with the hsp60 promoter 
but not with any other promoters. This may explain the low detection of (3-lactamase 
activity with hsp60 promoter based plasmids in BCG (see Chapter 6).
By infecting mouse macrophages with rBCG containing the (3-lactamase reporter 
gene under expression of various promoters and signal sequences, and measuring the 
level of activity of (3-lactamase using nitrocefin, the strength of promoters and signal 
sequences were determined. The results for three separate experiments are shown in 
Figure 4.6. The same pattern of P-lactamase activity was observed as those from in 
vitro homogenized samples of rBCG except that they were lower by 50%-70%. The 
reason for lower activity is probably due to the calculation of p-lactamase activity 
where contamination of macrophage proteins had interfered with the total amount of 
protein used and hence lowered the specific activity of the enzyme.
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Figure 4.4. p-lactamase activity in E, coli DH5a 
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The above figures show the comparative activity of mycobacterial promoters and signal sequences in supernatant and sonicated E. coli. The Mactamase activity was assayed by 
measuring the initial rate of hydrolysis (15 min) of a IfiOpM solution (1 ml) of nitrocefin in 
100 mM phosphate buffer pH 7.0. TTiese results are the average of four separate experiments. 
A unit (U) is defied as Ipmole/min.
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The above figures show the comparative activity of mycobacterial prtMuoters and signal sequences in supernatant and homogenized rBCG. The p-lactamase activity was assayed by measuring the initial rate of hydrolysis (15 min) of a lOOpM soluticm (1 ml) of nitrocefin in 100 mM plK)sphate buffer pH 7.0. These results are the average of fcmr separate experiments. 
A unit (U) is defiaid as Ipmole/min.
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Figure 4.6. p-lactamase activity in rBCG in vivo
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The above figure shows the ccanparative activity of mycobacterial promoters and signal sequences in rBCG during intracellular growth in J774 mouse macrophage for 20 hours. The 
P-lactamase activity was assayed by measuring the initial rate of hydrolysis (15 min) of a lOOpM soluticm (1 ml) of nitrocefin in 100 mM phosphate buffer pH 7.0. These results are of 
four separate expremaits. A unit (U) is defiend as Ipmol^min.
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4.7. Discussion
A reliable and reproducible system was established to evaluate mycobacterial 
translational signals in both the extracellular and intracellular environment using the 
E. coli P-lactamase reporter gene. In this system for the cloned DNA to generate 
P-lactamase activity, a promoter with or without a signal sequence, a ribosome- 
binding site, and a start codon in the correct reading frame must be provided.
Activity of the E. coli P-lactamase reporter gene was measured in E. coli DH5a, 
M  smegtnatis mc^ 155 and M  bovis Pasteur. However, the native P-lactamase 
activity in M  smegmatis msP- 155 was very high and reliable data could not be 
obtained from this species of mycobacteria transformed with the plasmid constructs. 
Properties of M  bovis P-lactamase are so far unknown but like its M  fortuitum 
counterpart, the M  smegmatis mc^ 155 p-lactamase enzyme, is a member of 
molecular class A P-lactamase (Quinting et ah, 1997).
The activity of mycobacterial hsp60 promoters in macrophages infected with rBCG 
expressing the lacZ gene was investigated by Dellagostin et a l, (1995). In that study, 
however, p-galactosidase activity was assessed by fluorescence microscopy using a 
fluorescein-conjugated substrate. In addition in an attempt to quantify 
p-galactosidase activity, fluorescence of infected macrophages was measured by 
flow cytometry and expressed as arbitrary units. The novelty of the present study is 
the development of a system, which allows rapid and reproducible quantification of 
mycobacterial promoter expression by directly assessing p-lactamase activity as a
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fonction of the number of bacteria grown intracellularly. By using this method, the 
inducibility of promoters during intracellular growth could be accurately compared 
with that obtained during in vitro growth. However when nitrocefin activity of 
rBCGs was measured in vivo using a cell line macrophage J-774, upregulation of the 
18-kDa promoter during intracellular growth was not observed as described by a 
previous study (Dellagostin etaL, 1995).
Nevertheless, the system described here will allow a large number of potential 
promoters from the library to be screened in order to isolate further potentially usefol 
promoters for recombinant vaccine developments. Identification of genes that are 
selectively expressed during intracellular growth may also be used to identify 
virulence genes of M  tuberculosis and to investigate the involvement of specific 
genes in the survival ofM  tuberculosis within macrophages.
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Expression of Recombinant Diphtheria Toxin Gene
Chapter 5
5.0. Introduction
In the previous chapter (Chapter 1), the feasibility of using BCG as a recombinant 
vaccine vehicle was thoroughly explained. Also, the different genetic vehicles as 
well as the different ways of expression of foreign genes in BCG were explained. In 
the latter part of that chapter, factors limiting the expression of foreign genes such as 
the translation-level (codon usage), posttranslational modification, protein folding, 
and degradation were reviewed. Finally, the significance of the RBS region, G+C 
contents (predominance of G/C at position 3), the importance of the -10 and -35 
distances, other features of the mycobacteria promoter, and gene upregulation in vivo 
were reviewed.
A combination of promoters and signal sequences were used to construct plasmids to 
express foreign genes cytoplasmically, as membrane-associated lipoproteins, or 
secreted outside rBCG as native proteins. The possible responses of the immune 
system and protective immunity were discussed in Chapter 3.
The entire nuclear protein of Respiratory Syncytial Virus (RSV) was RT-PCR 
amplified and cloned into previously constructed plasmids for expression as shown 
in Chapter 3. However, no expression signal was detected using immunoblotting as 
the detection system in either M  smegmatis or M. bovis BCG. Later in this chapter 
the possible reasons for its failure will be discussed. One obvious factor limiting the 
expression of foreign genes in mycobacteria is codon usage due to its high GC 
content (65%) which is reflected in a bias for codons with G or C at the third
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position. The entire diphtheria toxin gene fragment B (DtxB) of Corynehacterium 
diphtheriae was chosen as a foreign gene for expression. This choice was made 
because of the similarity of the genus Corynehacterium to Mycobacterium. Although 
it must be mentioned that the GC contents of DtxB is low (42%) compared to that of 
mycobacteria (65%).
5.1. Material & methods
All material and methods for the cloning and expression as well as the transformation 
are the same as described in Chapter 2. In this study M. bovis BCG substrain Pasteur 
(ATCC 35748) M  smegmatis mc  ^ 155 and E. coli DH5a were used for expression.
5.1.1. Construction of expression plasmids
5.1.1.1. PCR amplification of DtxB gene
A toxin producing (+++) C. diphtheriae strain (laboratory collection reference No. 
D4433) was used to provide a target template to amplify the DtxB gene. After 
growing C. diphtheriae on blood agar overnight, a loopful of colonies was mixed in 
an eppendorf tube containing 500}t1 of sterile water. The tube was placed in boiling 
water for two minutes to rupture the bacterial cell membrane and release 
chromosomal DNA. After brief centrifugation, the supernatant was separated and 
used as a template for PCR amplification. Using the primers DtxB -IF (5’-GTT 
CTAGAGCAGAGCTCATTGTCA-3') and DtxB -IR (5 -CGAAGCTTGACCCCA 
CTA-3’) containing Xbal and Hindlll restriction enzyme recognition sites 
respectively. A 1040bp PCR fragment corresponding to the entire coding sequence
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of the DtxB gene was generated by PCR using C  diphtheriae genomic DNA as 
template. After double digestion with Xbal and Hindlll, the 1040bp PCR fragment 
was ligated into the following plasmids: pUS972, pUS973, pUS974, pUS2004, 
pUS2000, pUS2001, pUS2002, pUS976, pUS2005, and pUS2006 generating: 
pUS2100-pUS2109 respectively.
All of the above plasmids were constructed as described in Chapter 3. As usual, all 
newly constructed plasmids were redigested and partially sequenced to confirm the 
right construction. Schematic representations of plasmids construction are shown in 
Figure 5.1-3. A summary of plasmids containing DtxB can also be seen in Table 5.1.
5.I.I.2. Antibodies used in this study
The following moclonal and polyclonal antibodies were used in this study.
Antibody Source
Anti-RSV nuclear protein/monoclonal Dr. G Toms, University of Newcastle
Anti-RSV nuclear protein/polyclonal Novagen
Anti-Diphtheria toxin/polyclonal Biosource
Anti-Diphtheria toxin/polyclonal Cambio
Anti-Diphtheria toxin/polyclonal Zymed
Anti-Diphtheria toxin/polyclonal Dako
Anti-FLAG/monoclonal Sigma
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hsp60 promoter from BCG. 0.4 kb fragment containing 
383 bp of 5’ regulatory region, plus the first 6 codons and DtxB.
PÜS21Q1 hsp60 DtxB
hsp60 promoter from BCG. 0.4 kb fragment containing 383 bp
of 5’ regulatory region, plus MT-19 acylation signal sequence from MTB and DtxB.
hsp60 MT-19 DtxB
hsp60 promoter from BCG. 0.4 kb fragment containing 383 bp
of 5’ regulatory region, plus 85A secretional signal sequence from MTB and DtxB.
hsp60 85AS DtxB
Figure 5.1 Schematic representatims of plasmids pUS2101, pUS2102 and pUS2103 construction. Plasmid pUS972 was used as backbone vector and all promoters were clcmed into the Kpnl site, signal sequences were cloned into the BamHI site and DtxB was clcmed into the Xbal site.
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18-kDa promoter from M  leprae, 0.3 kb fragment containing 
266 bp of 5’ regulatory region, plus the first 6 codons and DtxB.
PÜS2104 18-kDa
M tflriV -’
18-kDa promoter from M leprae, 0.3 kb fragment containing 266 bp
of 5’ regulatory region, plus MT-19 acylation signal sequence from MTB and DtxB.
pUS2105 18-kDa MT-19 DtxB
18-kDa promoter from M, leprae, 0.3 kb fragment containing 266 bp 
of 5’ regulatory region, plus 85A secretional signal sequence from MTB and DtxB.
pUS2106 18-kDa 85AS DtxB
Figure 5.2 Schematic representaticms of plasmids pUS2104, pUS2105 and pUS2106 
ccMistruction. Plasmid pUS972 was used as backbone vector and all pixxnoters were cloiKd into the Kpnl site, signal sequences were cloned into the BamHI site and DtxB was cloned into the Xbal site.
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85A promoter from MTB. 0.7 kb fragment containing 669 bp of 5’ 
regulatory region, plus its own secretional signal sequence from MTB and DtxB.
pUS2107 85AS DtxB
85A promoter from MTB. 0.5 kb fragment containing 489 bp
of 5’ regulatory region, plus acylation signal sequence from M  leprae and DtxB.
PUS2108 85A MT-19 DtxB
MT-19 promoter from MTB. 0.5 kb fragment containing
514 bp of 5’ regulatory region, plus its own acylation signall sequence and DtxB
pUS2109 MT-19 MT-19 DtxB
Figure 5.3 Schematic representations of plasmids pUS2I07, pUS2108 and pUS2109 (xxistruction. Plasmid pUS972 was used as backbone vector and all promoters were cloned into the Kpnl site, signal sequences were clcmed into the BamHI site and DtxB was denied 
into the Xbal site.
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Table 5.1 . Summary of shuttle plasmids containing DtxB
Plasmid Promoter Signal Sequence
pUS2100 - -
pUS2101 hsp60 -
pUS2102 hsp60 MT-19
PÜS2103 hsp60 85A
pUS2104 18-kDa -
PÜS2105 18-kDa MT-19
PÜS2106 18-kDa 85A
pUS2107 85A 85A
pUS2108 85A MT-19
pUS2109 MT-19 MT-19
The table above shows the list of promoter and signal sequences driving DtxB gene used in this study.
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5.2. Results
5.2.1. Expression of RSV nuclear protein
Expression levels of a foreign gene often vary in different strains of a given 
prokaryotic host species. One obvious factor limiting expression of a foreign gene in 
mycobacteria is codon usage due to its high GC content (65%) which is reflected in a 
bias for codons with G or C at the third position. Using western blotting as the 
method of detection, total viral protein was denatured and run on a SDS-PAGE gel. 
A band of a 42-kDa corresponding to the nuclear protein was detected using a 
monoclonal antibody raised against the RSV nuclear protein (provided by Dr, G. 
Toms; University of Newcastle).
However, the expression of the same gene under the control of the hsp60 promoter or 
18-kDa promoter in E. coli and later in rBCG were negative but it was detectable in a 
commercial E. coli expression vector (pMalc) with an inducible promoter (ptac). A 
more reasonable explanation could be the incorrect or inefficient posttranslational 
modification and improper folding of the RSV nuclear protein. Viral proteins are 
known for their requirement for posttranslational modification and proper folding in 
order to be functional and stable. A total of four different commercial polyclonal 
antibodies that were raised against RSV nuclear protein were used, however all failed 
to detect any signal. Therefore, low codon usage of the RSV nuclear protein in rBCG 
may well be the reason for lack of expression of this antigen.
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5.2.2. Expression of DtxB gene
The expression of DtxB gene in E, coli under the control of a mycobacterial 18-kDa 
promoter (pUS2104), a promoter known to be functional in E. coli, was readily 
detectable using western blotting and a polyclonal antibody (Cambio) that was raised 
against the Dtx. The same plasmid (pUS2104) was transformed into M. smegmatis 
mc  ^ 155 and expression detection was performed. Although the expected band of 
about 40-kDa was detected, the cross-reactivity of the antibody to unrelated 
mycobacterial proteins was veiy high and in the case of BCG, blocked the whole 
nitrocellulose membrane. Various techniques were attempted to remove the non­
specific antibodies such as the use of a filter membrane containing homogenized 
total BCG protein to absorb non-specific antibodies or simply reusing a diluted 
antibody solution. However, both techniques proved to be unsuccessful. A total of 
four different anti-diphtheria toxin polyclonal antibodies were tried. Unfortunately 
all of them seemed to have used Freund's Complete Adjuvant to raise antibody, 
which interfered with the detection system.
5.2.3. Expression of DtxB gene after tagging with “FLAG”
To overcome the cross reactivity problem, an epitope of eight amino acids 
(DKYDDDDK) named “FLAG” was cloned in frame at the N-terminus of the DtxB 
protein. This was done by incorporating the epitope gene (24bp) into the PCR 
oligonucleaotide primer, and amplifying the FLAG- DtxB gene. The FLAG epitope 
was chosen because of its specific monoclonal antibody and its short (8 amino acids) 
polypeptide size, which is unlikely to interfere with any animal study if the rBCG
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was going to be used as a recombinant vaccine. The detection signal of the expressed 
DtxB gene, using pUS2104 in E. coli and anti-FLAG monoclonal antibody, was 
probably ten times higher than the previously used polyclonal antibodies (anti­
diphtheria toxin).
5.2.4. Expression of DtxB tagged in M smegmatis
Next, all of the constructed plasmids (pUS2100-pUS2109) were transformed into the 
M  smegmatis mc^ 155 and western blotting was performed after growing a single 
colony for three days for each of the transformants (Figure 5.4). Expression was 
detected with all of the plasmids except the promoterless DtxB plasmid (pUS2100) 
as was expected. The level of expression was more or less the same for all of the 
plasmids except for the 18-kDa promoter (pUS2104), when using an equal amount of 
total protein for each of the recombinant M  smegmatis mc  ^ 155. However the level 
of expression for thel8-kDa promoter (pUS2104) combined with either MT-19 or 
85A signals was as strong as the other plasmid constructs. The only drawback was 
the failure to detect expression when the supernatant of promoter 85A with its 
secretional sequence (pUS2107) was used. Trials with concentrated supernatant, 
using commercial protein concentration columns with protein cut-off filters of 10k 
IcDa and using 10 ml of rBCG supernatant which was reduced to less than 0.5 ml 
after concentration, still failed to give any signals. This could be due to the nature of 
the diphtheria toxin where part of the protein may have been trapped within the cell 
because of the different structure of Comeybacterial to Mycobacterial cell walls.
106
Chapter 5
5.2.5. Expression of DtxB tagged in M. bovis BCG
Recombinant plasmid pUS2101 {hsp60 promoter), with one of the strongest known 
promoters in mycobacteria, was transformed into M  bovis BCG Moreau. This 
substrain was chosen because our colleagues found it to be “superior” in terms of 
foreign protein expression than other substrains. However, no expression was 
detected with any of the hsp60 based plasmid constructs. The transformed BCG 
plasmid DNA was used to check the stability of the recombinant plasmids by 
retransforming the plasmids back into £. coli. After analysing many E. coli colonies 
(30 colonies), none of the colonies seemed to have retained the complete intact 
plasmids (results are not shown). Therefore it was decided to use other BCG 
substrains, namely Pasteur and Tokyo, to see if better stability of the hsp60 promoter 
driving the DtxB gene could be achieved. Initial investigations, analysing a further 
30 & coli colonies, showed that both Pasteur and Tokyo BCG substrains were 
markedly better (7/30; 11/30) respectively at retaining the complete intact plasmids. 
These results have prompted us to ftnther investigate the rate of deletion initiated by 
the hsp60 promoter in other BCG substrains (Chapter 6).
Since BCG Pasteur is a vaccine substrain and most widely used in mycobacteriology 
laboratories, all of the constructed plasmids (p U S2100-p U S2109) were transformed 
into this substrain. The rBCG was grown in 175cm^ culture flasks containing 200 ml 
7H9, 10% OADC and 20pg/ml kanamycin for 5 days after an initial 1/100 dilution of 
a ‘fresh’ 10 ml culture. The entire 200 ml was harvested by centrifugation at 4000 g 
for 10 minutes. The pellet was washed once with lOOmM tris-HCl (pH 7.5) and 
centrifuged as above before being homogenized in the same solution and western
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blotting was performed as described in Chapter 2. Expression was detected with all 
of the plasmids except the promoterless DtxB plasmid (pUS2100) as was expected 
(Figure 5.5). The level of expression was more or less the same for all of the 
plasmids except for 18-kDa promoter driving DtxB gene (pUS2104) where a faint 
band was detected, but when combined with MT-19 or 85A signals it was as strong 
as the others, when using an equal amount of total protein for each of the rBCG. 
However, concentrated culture supernatant of promoter 85A with its secretional 
sequence (pUS2107) failed to give any signals in immunoblotting.
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Figure 5.4 Western blot of DtxB protein in M, smegmatis
9  10 11 12
46.5 kDa — ^
37.5 kDa — ►
42 KDa
Lane Plasmid Promoter Signal Sequence5 pUS2100 - -
4 PÜS2101 hsp60 -
3 PÜS2102 hsp60 MT-19
2 PÜS2103 hsp60 85A1 PUS2104 18-kDa -8 PÜS2105 18-kDa MT-199 PÜS2106 18-kDa 85A10 PÜS2107 85A 85A11 PÜS2108 85A MT-19
12 PUS2109 MT-19 MT-19
The above figure shows western blotting of recombinant M. smegmatis mc^  155 grown in NB2 broth ccaitaining kanamycin (30 pg/ml) for 24 hours. Lanes 6 & 7 are reccxnbinant E. coli DtxB gene under control of 18-kDa promoter, lane 1, pUS2104; laiw 2, pUS2103; lane 3, pUS2102; lane 4, pUS2101; lane 5, pUS2100; lane 8, pUS2105; lane 9, pUS2106; lane 10, pUS2107; lane 11, pUS2108 and lane 12, pUS2109. The above immunoblotting was detected using anti-FLAG mcmoclonal antibody.
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Figure 5.5 Western blot of DtxB protein in BCG
46.5 kDa
37.5 kDa
/  8 9 10 11 1?
<----- 42 KDa
Lane Plasmid Promoter Signal Sequence2 PÜS2100 - -
3 PÜS2101 hsp60 -
4 PÜS2102 hsp60 MT-195 PÜS2103 hsp60 85A6 PÜS2104 18-kDa -7 PÜS2105 18-kDa MT-198 PÜS2106 18-kDa 85A9 PÜS2107 85A 85A10 PÜS2108 85A MT-19
11 PÜS2109 MT-19 MT-19
The above figure slwws western blotting of rBCG Pasteur substrain expressing DtxB gene.
The rBCG was grown in 175 cm^  culture flask in 200 ml of 7H11 broth ccaitaining 10% OADC and kanamycin (20 pg/ml) for 5 days after initial 1:100 dilution with fireshly grown culture. Lanes 1 & 12 are recombinant E. coli with DtxB gene under control of 18-kDa 
promoter, lanes 2-11 are rBCG plasmids pUS2100-pUS2109 respectively. The above immunoblotting was detected using anti-FLAG monoclonal antibody.
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5.3. Discussion
The failure to detect rBCG expressing RSV nuclear protein could be a result of a 
combination of factors such as: i) nucleotide base composition (30% GC content in 
RSV compared to 65% GC content in mycobacteria), ii) lack of transfer RNA coding 
for those codons which are rare in mycobacteria. For example, of six available 
arginine codons, CGC, CGG, CGU, account for 84% of the arginine residues in 
M  tuberculosis complex, while in RSV the predominant arginine codon was AGA, 
which was rearly found to be used in M  tuberculosis complex (Andersson & Sharp, 
1996; Dale & Patki, 1990). And finally, post-translational modification and improper 
folding of viral protein in a foreign environment and hence, failure of dififerent 
antibodies to recognise the epitope site(s).
To overcome the problem of codon usage in mycobacteria, Norazmi et a l, (1999) 
used assembly PCR to assemble a series of oligonucleotides to generate a synthetic 
fragment of a 300 bp malaria epitope. It was successfully cloned into a plasmid 
vector and expression of the epitope in rBCG was detected. However, in the case of 
RSV nuclear protein where the gene size is over Ikb, this approach would be more 
difficult.
The entire C  diphtheriae fragment B toxin gene was cloned into plasmid-based 
vectors under the control of a combination of various promoters and signal 
sequences. The expression of this gene was successfully detected, in both 
recombinant M  smegmatis mc^ 155 and BCG Pasteur tagged with a very short
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epitope (FLAG), using mouse monoclonal antibody. Whereas DtxB was readily 
detectable in crude extracts of recombinant cells, its concentration in concentrated 
culture supernatants was too low to be detected by immunoblotting, although enzyme 
activity of P-lactamase could be readily detected in culture supernatants (see Chapter 
4). Kremer et ah, (1995) obtained similar results using phoA as a reporter gene, 
where phoA activity was readily detectable in the supernatant but no signal was 
detected by western blotting even in a concentrated supernatant samples.
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Stability of foreign gene in different BCG substrains
Chapter 6
6.0. Introduction
Since 1921, the original BCG vaccine strain has been developed into several 
different substrains and delivered for propagation in different laboratories all over the 
world for the production of BCG vaccines. The BCG substrains were propagated in 
various countries in different ways, such as subculturing on potato or Sauton media 
and harvesting after a varying number of passages, until the establishment of seed 
lots by freeze-drying. These have led to the emergence of different variants during 
the production of BCG vaccines. Of more than 50 strains of BCG known, only six 
are currently in extensive use today: Connaught, Danish, Glaxo, Moreau, Pasteur and 
Tokyo. All of these strains show morphological, biochemical, and immunological 
differences (Bunch-Christensen, 1977; Gheorghiu & Lagrange, 1983; Ladefoged et 
al., 1970; Milstein, 1989.; Minnikin ef a/., 1984; Osborn, 1983).
A variety of in vitro and in vivo tests demonstrated that BCG strains are 
distinguishable (Dubos & Pierce, 1956; Dubos & Pierce, 1956; Dubos & Pierce, 
1956; Dubos et ah, 1956; Gheorghiu & Lagrange, 1983). Recent molecular work has 
demonstrated differences between BCG and M. tuberculosis (Mahairas et ah, 1996) 
as well as genetic distinction between BCG strains (Collins & De Lisle, 1987; 
Fomukong et ah, 1992). Since BCG strains also vary in protein expression (Harboe 
& Nagai, 1984), lipid composition (Minnikin et ah, 1984) and behaviour in both 
laboratory animals (Bolanos, 1948; Dubos & Pierce, 1956; Frappier, 1971; 
Ladefoged et ah, 1970; Lagranderie et ah, 1996) and humans (ten Dam, 1984), an 
understanding of their genetic differences may provide insights into the determinants
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of protective immunity. Recently, Oettinger et ah, (1999) and Behr & Small, (1999), 
have reviewed the molecular and biochemical differences among BCG substrains 
linking them through a historical prospective. Their studies demonstrated clear 
genetic and immunological differences between ‘early’ and ‘late’ BCG substrains.
It must be mentioned that it has never been possible to relate the varying efficacy of 
BCG in different field trials to the substrains used (Bjartveit & Waaler, 1995; Hart & 
Sutherland, 1977; Milstein, 1989; Ponnighaus et al., 1992). As a consequence, the 
WHO has stated that the major internationally used BCG substrains tested in 1989; 
Danish, Glaxo, Pasteur and Tokyo, are all equally suitable for immunization against 
tuberculosis (Milstein, 1989).
Some of the genetic differences between the three BCG strains used in this study are 
compared with virulent M  bovis and are summarized in table 6.1.
Table 6.1 Genetic differences among BCG substrains
Name of strain Year obtained Copies ofIS6110 Mpt64 ESAT-6
M  bovis 1-6 4- +
Moreau 1924 1-2 + -
Tokyo 1925 3 + —
Pasteur 1961 1 —
The above table summarizes results of IS6110, Mpt64 and ESAT-6 typing of BCG strains and the year tlie strain was obtained is also shown.
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6.1. BCG substrain
6.1.1. BCG Moreau
In 1924, a BCG strain was received by Dr Moreau in Montevideo and was later 
passed in 1931 to Assis, a Brazilian, who named the strain BCG Moreau (Crispen, 
1989), The culture was propagated on different media and it was not until the 1950s 
that it was ffeeze-dried. In the early 1960s, two ampoules of the freeze-dried batch 
were brought to Copenhagen and on request from the WHO; a small batch of freeze- 
dried vaccine was produced (Oettinger et al., 1999). After being tested in vitro and in 
vivo, this batch was nominated as a primary seed lot.
6.1.2. BCG Tokyo
In 1925, Dr Shiga took a seed culture from Institut Pasteur to Tokyo (Oettinger et ah, 
1999). There was large-scale production in 1946-7. The first attempts at 
lyophilization were in 1943, and BCG Tokyo has been used as a freeze-dried vaccine 
since 1950. In 1960, a 172"^  ^ transfer on bile-potato medium was freeze-dried and 
adopted as the primary seed lot (Osborn, 1983). This substrain is therefore known as 
the BCG Tokyo strain 172. The Tokyo seed has characteristics that are quite distinct 
from all other strains in use. It is characterized by an unusually high colony count 
before freeze-drying and in the final vaccine. The bacteria are small and have a 
metabolism different in certain aspects from that of other strains (Oettinger et al., 
1999).
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6.1.3. BCG Pasteur
In 1961, the present Pasteur strain was derived from a single colony of 30 colonies 
examined that yielded cultures, which, especially in terms of pigmentation, had 
properties most closely corresponding to the original description by Calmette. This 
strain, 1173P, was freeze-dried and the second batch is now the primary seed lot of 
the “Paris or French strain” (Gheorghiu & Lagrange, 1983). There has not been any 
written report connecting what has happened to the original Pasteur strain from 1921 
or which, if any, of the three strains mentioned by Calmette and Guerin was chosen 
to produce BCG vaccine after 1932 (Osborn, 1983). The 1173P Pasteur substrain 
was distributed to many other countries, some of which continue to produce BCG. 
However, the strain is no longer used for BCG production in France (Oettinger et al., 
1999).
6.2. Stability of hsp60 promoter gene fusion & expression 
on a multicopy plasmid vector
Expression levels of foreign proteins in rBCG are influenced by many factors as 
already explained in Chapter 1. Plasmid-based expression systems extend the 
capabilities of phage-based systems by providing increased cloning capacity, 
increased copy number in the mycobacterial host, and ease of manipulation. As 
single-copy elements replicating with the bacterial chromosome, foreign genes from 
integrating vectors have had lower expression levels, in most cases, than the same 
genes expressed from multicopy plasmids.
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The only study so far comparing the expression of a foreign gene (OspA) in different 
BCG substrains under the control of the hsp60 promoter with or without MT-19 
lipoprotein leader peptide fusion on an extrachromosomal vector yielded rather 
confusing results (Burlein et al., 1994). For instance, Pasteur gave a high level of 
expression with both hsp60 and hsp60iMIA9 leader peptide; Phipps expression was 
high in hsp60 but undetectable with hsp60fMI-\9 leader peptide; Tice and Moreau 
were negative in hsp60 yet strong with hsp60iMT’-l9 leader peptide, while, no 
expression was detected in either recombinant by Tokyo.
Currently, one of the most efficient mycobacterial promoters available and used 
extensively in genetic mycobacteriology laboratories is M. bovis BCG hsp60. 
However, there are serious doubts about its stability in driving a foreign gene when 
on a plasmid vector. Results from previous two chapters (Chapters 4 & 5), showed 
various deletions in plasmid constructs with hsp60 promoter base. Therefore, a study 
was made of the use of hsp60 as a promoter and plasmid as a vector vehicle for 
expressing a foreign gene in different BCG substrains, including the stability of the 
constructs.
6.3. Aim of the study
The aim of this study is to verify and quantify the extent of a deletional effect of a 
foreign gene under the control of the hsp60 promoter, in three commonly used BCG 
substrains. Having done this, an attempt was made to determine whether the level of 
expression of a foreign gene also differed amongst the three BCG substrains.
1 1 8
Chapter 6
6.4. Method & design of the study
6.4.1. Material & methods
6.4.1.1. Rapid colony lysis
A single E. coli colony was mixed in small eppendorf tube with 15 pi of the rapid 
lysis solution (10 ng/ml RNAse in 1 x loading buffer) and 15 pi of 1:1 
phenol/chloroform. The tube was vortexed briefly and centrifuged at 10,000 g for 1 
minute. A 15pl aliquot of the supernatant was ran on 0.8% (w/v) agarose gel.
6.4.1.2. Vector construction
The stability test plasmid pUS2101 consists of an expression vector based on pUC19 
carrying the kanamycin-resistance gene (aminoglycoside 3'-phosphotransferase) 
from Tn903, a mycobacterial origin of replication from pAL5000, and the promoter 
as well as the 5'-terminal sequence of the hsp60 gene from M bovis BCG in fusion 
with (DtxB) foreign gene (Figure 6.1).
Figure 6.1 Diagrams of pUS973 and pUSllOl
EcoK I (I)
kan(R)
oriE pUS973 
3984 bp
£coR 1
oriM
OriE
DIB
OriM
XbfA (2059) 
RBS
phspeo
ffc*l(247())
Plasmid pUS973 when digested with restriction endcmuciease EcoRI gives three fragments of 1387 bp, 1011 bp and 1586 bp, while plasmid pUS2101 when digested with restriction aWonuclease EcoRJ gives three fragments of 2470 bp, 1011 bp and 1586 bp. This enzyme was used to determine the length of plasmid deletions.
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6.4.2. Study design and plasmid isolation & screening from BCG 
substrains
Vector pUS2101 was electroporated into competent BCG substrains Moreau, Tokyo 
and Pasteur and selected on kanamycin plates. Five different transformations were 
carried-out for each substrain. After three weeks of growth, five individual colonies 
from each plate for each substrain were grown in 7H9 broth, containing the selective 
antibiotic (kanamycin) and enrichment, for three weeks (25 broths for each 
substrain). A modified protocal from Madiraju et a/., (2000) was used to isolate 
plasmids from mycobacteria using glass beads. The cells were harvested and the 
pellets were washed once with distilled water before they were homogenized using 
glass beads (see section 2.2.17.). The homogenized tubes were briefly centrifuged in 
a microcentrifiige and 2 \x\ of the supernatant containing plasmids were used to 
transform E. coli DH5a.
Next, five individual E. coli colonies from each plate were used for rapid lysis 
screening of colonies (125 colonies for each substrain).
6.5. Results
6.5.1. Colony rapid lysis screening of JSl coli
A rapid lysis of E. coli colonies was performed to provide a rapid screen of the 
deletion events. Plasmids pUS973 (hsp60) and pUS2091 {hsp60 and DtxB) were 
used as negative and positive controls respectively (Figure 6.1), A positive (P) was 
recorded, to indicate that the sample plasmid was the same size as the positive 
control. A short deletion (SD) was recorded, to indicate that the sample plasmid was
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a slightly smaller size than the positive control. A long deletion (LD) was recorded, 
to indicate that the sample plasmid was the same size or smaller than the negative 
control. In all cases, the plasmid sizes from the individual E. coli colonies of a single 
rBCG culture were identical. Examples of plasmid DNA deletion patterns on an 
agarose gel can be seen from Figure 6.2. The absence of variation between E. coli 
clones containing plasmids from the same BCG transformant, coupled with the high 
degree of variation between BCG transformant colonies, suggests that deletions 
occur mainly or exclusively early on transformation and are subsequently fixed.
6.5.2. Restriction digestion screening of plasmid DNA
Plasmid DNA was purified from a single colony from each plate of E. coli 
(positive/negative) and digested with EcoRI or Xbal and Hindlll to assess the size of 
the plasmid. All positive (without apparent deletion by gel electrophoresis) plasmids 
were further investigated by sequencing while, all negative (clear deletion by gel 
electrophoresis) colonies were digested by restriction enzyme {EcoRI) to determine 
the extent of deletion by the length of the digested band(s) on an agarose gel. 
Examples of the degree of deletion assessed by restriction digest by EcoRI are shown 
in Figure 6.3.
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Figure 6.2 Rapid lysis of E. coli colonies
1 2  3 4 .  5 ^  -7 a* 9 10 II 13 14 15 16
C hrom osom al DNA 
Plasm id DNA
17 18 l ê  21 22 23 24- 25 26 27 2& 29 30 31 3 2
Intact plasm id —  
Deleted plasm id ^ 1
33 34) 35 36 37 38 39 40 41, 42 43 44 45 46 47 48
An example of rapid colony lysis of E. coli ran on 0.8% agarose gel as described in section 
6.5.1.The plasmids were recovered from rBCG and transferred back into E. coli. Lanes 1,17 
and 33 are positive control (pUS2101); while the rest are the samples. The plasmid size for 
each of the ten E. coli colonies used from a single rBCG sample is always the same. 
Therefore, subsequently only five E. coli colonies from each plate were screened.
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Figure 6.3 Samples of digested plasmids from E. coli
M l  M 2  1 2 5 4 5 6 7 H 9 10 11 12 13
4361 bp -----
2322 bp ------
2027 bo
1353 bp -----
1078 bp -----
M l  M 2  H  15 16 17 i«  19 2« 21 22 23 24 25 26
The above agarose gel shows E. coli plasmid DNA samples digested with EcoRI. Marker M 1 
is AyHindlll, while M2 is (j)x 174/HaeIII. Lane 1 and 14 are plasmids without DtxB gene 
(pUS973), while lane 2 and 15 are plasmid with DtxB (pUS2101). The rest of the lanes are 
samples with various degree of deletion. These samples were used to calculate the degree of 
the deletion by estimating the sizes of the digested bands.
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6.5.3. Stability test o f rBCG substrains
Results of stability of plasmid DNA (pUS2101), recovered from rBCG in three 
different BCG substrains are shown in table 6.2. This table shows the proportion of 
rBCG retaining intact plasmid DNA confirmed by sequencing the hsp60 promoter 
region. The percentage of the deletion as well as median length of deletion 
(estimated), for each rBCG substrain can also be seen. Data from this table and 
estimated length of deletion were used (see 6.5.5.) to perform statistical tests 
investigating whether there was a significant difference between these three BCG 
substrains in terms of retention and length of deletion of plasmid DNA.
6.5.4. Other plasmids stability test
A plasmid stability test was performed with various plasmid constructs with the same 
foreign gene (DtxB) driven by various promoters other than hsp60 in the BCG 
Pasteur substrain. Lists of various plasmid constructs and results of plasmid stability 
test are presented in table 6.3. This table also shows the results of a plasmid with a 
hsp60 promoter but without presence of a fusion gene and the same plasmid 
(pUS2101) used in this study but transformed into M  smegmatis mc  ^ 155 and 
screened for plasmid stability. Plasmid DNA recovered from each of the above 
plasmid constructs was digested with EcoRI for confirmation of complete intact 
plasmid. These results indicate that: i) plasmid DNA deletion occurs with only hsp60 
promoter in fiision with in this case foreign gene; ii) the deletion occurs only when 
the plasmid is transformed, into BCG but notM  smegmatis mc^ 155 orE. coli.
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6.5.5. Statistical analysis
6.5.5.1. Sample size calculation
Power calculations were performed to assess, if sufficient observations had been 
made to detect a significant (P <0.05) result. Using the minimum difference between 
the observations and the variation in the retention of the intact plasmid, power 
calculations indicated that screening 25 total BCG colonies for each substrain was 
more than sufficient to show a significant difference.
6.5.5.2. Plasmid deletion
One-way analysis o f variance (AND VA)
One-way analysis of variance followed by a Tukey-Kramer multiple comparison 
(post-hoc test) was performed to show any significant differences in terms of plasmid 
deletion among the three different BCG substrains. There was a significant 
difference in the percentage of colonies having a plasmid deletion between BCG 
Tokyo vs BCG Moreau with P< 0.01, however; there were no significant differences 
between Tokyo vs Pasteur or Pasteur vs Moreau with P> 0.05.
These results are expressed as five separately transformed replicate plates for each 
BCG substrain from which five individual colonies were randomly selected and 
screened for retention of the complete intact plasmid.
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6.5.S.3. Estimated length of deletion
The degree of deletion was compared in the three rBCG substrains. The rBCG with 
plasmid DNA deletion from the three substrains were digested by EcoRI and the 
degree of deletion was estimated. The digested band size estimation was done by 
plotting logarithm of molecular weight marker (bp) against the distance (mm) of 
digested band moved on agarose gel. The data is summarised in Table 6.4.
Table 6.4 Summary of rBCG substrains plasmid deletion
Group No. of rBCG 
colonies screened
Mean of 
deletion
SD Standard error 
of mean
Median Range
Pasteur 20 889 486.4 108.7 858 242-1771
Tokyo 18 387 370.6 87.3 259 43-1323
Moreau 24 1050 512.1 104.5 964 201-2350
One-way analysis o f variance (ANOVA)
One-way analysis of variance followed by a Tukey-Kramer multiple comparison 
(post-hoc test) was performed to show any significant differences in terms of degree 
deletion among the three different BCG substrains. There were significant 
differences between BCG Tokyo vs BCG Pasteur {P< 0.01) and BCG Tokyo vs BCG 
Moreau (P< 0.001); however there was no significant difference between BCG 
Pasteur vs BCG Moreau (P> 0.05) (Table 6.5).
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Table 6.5 Tukey-Kramer multiple comparisons test
Comparison Mean deletion difference (bp) difference P Value
Pasteur vs Tokyo 501 **P<0.01
Pasteur vs Moreau -160 nsP>0.05
Tokyo vs Moreau 662 ***P<0.01
These results are expressed based on the number of deleted individual rBCG colonies 
that were transformed back into E. coli and purified plasmid DNA was used to 
estimate degree of deletion after digestion with EcoRI.
6.5.6. Sequence analysis of plasmids with deletion
Random deleted plasmid DNA samples (17 in total) recovered from rBCG (see 
6.5.2) were sequenced. The extent of deletion ranged from 77 bp to more than 2.6 kb 
and matched those estimated by calculation to the nearest of 50 bp to 100 bp 
depending on degree of deletion. A specific region of DNA (coding for bases 2244 to 
2343) within the hsp60 promoter corresponding to the first transcriptional start (TS) 
(Gomez & Smith, 2000; Stover et al., 1991) site (at 2302) was found to be in 
common with nearly all samples sequenced (Figure 6.4).
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Filtre 6.4 Ddetion dT plasind pDSZlOl IX^ r^ KMK
ATGRBS TSh$p60 promoter region
U l l
2000 2090 2iœ 2150 2200 2250 2300 23S0 2400 2450 2500
regions of ddedon
The above figure shows DNA deletion of plasmid pUS2101 frcmi random samples of rBCG 
substrains. These deletions were determined by sequencing DNA recovered from rBCG 
transformants. The mtire hsp60 promoter region is shown by the arrow (2048-2463) as well 
as RBS (2102), ATG (2084) and TS (2302). A r^ion of about 100 bp is in ctxnmon with nearly all deletion sequenced (2244-2346). Although most clones contain this 100 bp 
deletion, some deletions are much longer going below 2000 and above 2500 sites (ckmes in the figure are shown terminating at these limits).
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6.5.7. Expression study
The three BCG substrains used in this study were analysed by SD S-PA G E  gel and 
C oom assie blue staining (Figure 6.5) or by immuniblotting with anti-FLAG  
m onoclonal antibody (Figure 6.6). The protein samples for im m unoblotting were 
those from rBCG sam ples with or without plasm id D N A  deletion used in this study. 
N o signal was detected in the case o f  sam ples with plasmid D N A  deletion from the 
three-rBCG substrains used. The im munoblot results are consistent with the 
suggestion that the deletion occurred at a very early stage o f the transformation i.e. 
during electroporation or just after transformation and during the recovery o f  rBCG.
Figure 6.5 Protein gel of different BCG substrains
The above SDS-PAGE protein gel shows various native and rBCG substrains expressing 
DtxB gene. Lane 1, BCG Moreau; lane 2, BCG Tokyo; lane 3, BCG Pasteur; lane 4, rBCG 
Moreau; lane 5, rBCG Tokyo and lane 6 rBCG Pasteur.
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Figure 6.6 Western blot of DtxB protein in various BCG substrains
M 1 2  3 4 5 6 7
46.5 KDa -----
37.5 KDa -----
The above figure shows western blotting of rBCG expressing DtxB gene in various BCG 
substrains using anti-FLAG monoclonal antibody. The proteins used for this western came 
directly frtxn samples with or without plasmid deletion from three different BCG substrains. 
Lane 1, E. coli expressing DtxB gene under ccmtrol of 18-KDa prc«noter used as positive control; lane 2, BCG Moreau with plasmid deleticm; Lane 3, BCG Moreau widiout ckleti<Hi; 
lane 4, BCG Tokyo with plasmid deletitm; Lane 5, BCG Tokyo without deletion; lane 6, BCG Pasteur with plasmid deleticm. Lane 7, BCG Pasteur without ckleticm
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6 .6. Discussion
The stability of the M  bovis hsp60 promoter on a plasmid based vector driving a 
foreign gene has long been of great concern. For instance, in our laboratory 
experience with the hsp60 promoter driving lacZ has shown various random 
deletions within the promoter as well as the lacZ gene (personal communication).
There were high proportions of deletions among the rBCG colonies screened, and the 
lowest was (72%) observed in the Tokyo substrain. Plasmids that were recovered 
from rBCG and later transformed into E. coli, showed the same result for all E. coli 
colonies screened for each rBCG colony. This implied that the deletions were 
occurring at a very early stage i.e. just after transformation of the plasmids into BCG. 
To test the hypothesis that the cause of plasmid deletions in BCG was the expression 
of a foreign protein, the rBCGs containing a promoterless DtxB gene and under 
control of various different promoters with or without signal sequences were 
screened for plasmid deletions. The results showed that all had retained complete 
intact plasmids.
To test whether the hsp60 promoter driving a foreign gene was also unstable in fast 
growing mycobacteria, a total of five recombinant M. smegmatis mc  ^ 155 colonies 
were screened. All of the colonies contained intact plasmid. Therefore, the deletion 
seemed to be caused by the hsp60 promoter in BCG. To test this the plasmid 
containing the hsp60 promoter but without any fusion gene was transformed into 
BCG Pasteur and later screened for deletion events. However, no deletion was
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observed after screening five separate BCG colonies. Again, this implied that 
deletion with the hsp60 occurs while it is driving, in this case, a foreign antigen on 
plasmid DNA in BCG.
In order to understand the length and site of deletion, plasmids were recovered from 
individual E. coli colonies analysed by restriction digestion and later by sequencing. 
These revealed that the deletion occurred within the hsp60 promoter and caused 
random deletion of the genes in either upstream or downstream directions. The 
length of deletion varied from less than 80bp to more than 2.6kb. Interestingly, 
lengths of deletion in BCG Tokyo (median 259bp) were smaller than BCG Moreau 
(median 964bp) or Pasteur (median 858bp). Furthermore, this study was able to 
locate a precise DNA region of about lOObp within the hsp60 promoter that was 
found to be in common with nearly all of the deletions occurring in all three 
substrains. It appears that deletions are restricted within this region, and are then 
extended to a variable extent. Furthermore, this process seems to be stimulated by 
events during electroporation. Possible mechanisms include a restriction system or 
DNA repair processes, with this region being for some reason hypersusceptible. 
However, the absence of deletions in the plasmid lacking the DtxB gene indicates 
that selection against expression of a foreign protein plays a significant role. The 
most likely hypothesis is therefore that there is a transient induction of the hsp60 
promoter immediately after electroporation leading to a lethal level of synthesis of 
the foreign protein, and hence the selection of mutants with deletions in the promoter 
region.
134
Chapter 6
In contrast to the previous study by Burlein et al., (1994), where differences among 
BCG substrains were observed, the results show that there were no differences in 
expression level of the DtxB gene with the three substrains used (as long as the 
‘right’ colony was used i.e. complete intact plasmid was retained) using 
immunoblotting as a detection method. The western blotting results of rBCG with or 
without plasmid deletion tend to support the scenario that the plasmids are stable 
after successful introduction of intact plasmids into BCG.
In conclusion, of the three BCG substrains tested for stability of the hsp60 promoter 
driving DtxB on an extrachromosomal plasmid, BCG Tokyo proved to be more 
stable and exhibit less degree of deletion than either BCG Moreau or BCG Pasteur. 
Furthermore, no differences were observed in the level of expression among the three 
BCG substrains when tested by immunoblotting.
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General Discussion
Chapter 7
Recent advances have increased the possibility of a new TB vaccine. Perhaps the 
most significant of these advances is the complete sequencing of the genome of 
M  tuberculosis (Cole et ah, 1998). The DNA sequence of the 4,000 or so genes will 
help to identify antigens that confer protective immunity and lead to various types of 
vaccine candidates. However, despite these advances, still little is known about the 
immunologic mechanisms that confer resistance to TB; therefore, there is a need to 
pursue many different types of vaccine candidates.
Of the different types of vaccines, DNA vaccines look most promising. The plasmid 
directly transfects a living cell, leading to the host becoming immunized against a 
heterologous protein produced by his own cells (Huygen, 1998). Various studies 
using a murine model have shown that DNA plasmid vaccination can lead to specific 
T-cell responses that contain TB infection (Delogu et al., 2000; Huygen et al., 1996; 
Li et a l, 1999; Lowrie et al., 1997; Lozes et a l, 1997; Ulmer et al., 1997). The 
duration of this effect, however, is unknown. Also, there are some unanswered 
questions regarding the safety of DNA vaccines. Several of these theoretical 
concerns are regarding the integration of plasmid DNA into the host genome, 
tolerance induction, and autoimmunity (Huygen, 1998).
The future challenge will be to establish the most efficient way to deliver these key 
antigens to the immune system. This could be either in the form of an optimised 
subunit vaccine or by utilizing some of the developed delivery systems such as 
nucleotide vaccines (Ulmer et al., 1993), recombinant Salmonella aroA or vaccinia 
virus (Lyons et al., 1990). So far no experimental vaccines have proved more
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efficient than BCG, so perhaps the greatest hope for a better vaccine would be an 
enriched BCG that over-expresses certain critical epitopes from the virulent 
mycobacteria. The réintroduction of genes deleted in BCG, such as genes coding for 
the secreted antigens ESAT-6 and MPT64, is one promising direction towards an 
improved vaccine against TB. It may also be beneficial to boost type 1 cytokine 
production by using rBCG that secrete cytokines such as IL-2 or IFN-7 (Murray et 
al, 1996).
Optimisation o f the immune response
This study has attempted to describe an approach towards the development of a 
rBCG vaccine effective against TB and indeed any other infectious agents. There are 
two major paths that one can pursue: firstly, identify protective antigens (i.e. proteins 
that are absent from BCG, present in M. tuberculosis and immunodominant for 
protective T-cells); secondly, to construct improved BCG vaccine strains which 
stimulate the optimum combination of T-cell populations required for protection. It is 
not yet known which approach will succeed and it is quite possible that a 
combination of both methods (i.e. expression of protective antigens by improved 
BCG) will provide the most efficient measure. This study has focused on improving 
BCG by endowing it with the capacity to introduce antigens into the MHC class I 
pathway in a more efficient way. Future experiments will show whether a broad 
array of T-cells is required for protection or, alternatively, whether a limited number 
of antigen-specific T-cell clones are sufficient. In the first case, improved BCG 
constructs expressing additional M  tubercîilosis-spQcxûc antigens would be the 
strategy of choice. In the latter case, subunit vaccines or heterologous recombinant
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vaccine carriers expressing a limited number of immunodomonant protective 
antigens would be satisfactory.
Expression o f foreign antigens
In the present study, the E. coli P-lactamase gene was used as a reporter gene in BCG 
both in vitro and most importantly in vivo. The (3-Iactamase gene was used as a 
marker to determine the strength of various promoters and signal sequences 
constructed to deliver antigens into the cytosol, as a membrane-bound lipoprotein or 
secreted from the bacilli. In vitro, the level of activity of the (3-lactamase enzyme 
detected in homogenised rBCG using a nitrocefm assay was the highest with the 85 A 
promoter and secretory signal sequence (pUS2097) among all constructed plasmids 
including either the hsp60 or 18-kDa promoters with a 85A signal sequence. Indeed 
the P-lactamase activity was higher (eight fold) with thel8-kDa promoter having a 
85 A secretory signal sequence than a 18-kDa promoter alone or with a MT-19 signal 
sequence. These observations suggest that the presence of the 85A signal sequence 
leads to increased production of the p-lactamase enzyme, possibly through an effect 
at either transcriptional or translational levels, although an effect on mKNA or 
protein stability cannot be totally excluded. Sequences other than promoters are 
Imown that can influence the level of transcription. These include enhancers and 
upstream activator sequences, although the effect of the 85A sequence does not 
conform to the usual models, being downstream of, and relatively close to the start of 
transcription. However, enhancers are for the most part undefined and seen mostly in 
eukaryotic cells (Lewin, 2000). Elements analogous to enhancers, called upstream 
activator sequence, are found in yeast. They can function in either orientation, at
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variable distances upstream of the promoter, but cannot function when located 
downstream, A bacterial enhancer provides a binding site for the regulator NtrC, 
which acts upon RNA polymerase using a promoter recognized by When the 
enhancer is placed upon a circle of DNA that is interlocked with a circle that contains 
the promoter, initiation is almost as effective as when the enhancer and the promoter 
are on the same circle molecule. But there is no initiation when the enhancer and 
promoter are on separate circles.
Since the P-lactamase has been used as a reporter gene in mycobacteria (M hovis 
BCG) both in vitro and in vivo, it may hold a greater potential for use in other species 
of Mycobacterium such as those of disease causing M  intracellulare and M  avium. 
With the onset of the AIDS epidemic, the M. intracellulare-M. avium complex 
(MAC) has become of high medical relevance, being the most common cause of 
disseminated bacterial infection and contributing to the morbidity and mortality of 
HIV infected individuals (Nightingale et al., 1992). However, their genetic 
manipulation remains very difficult. In fact, only recently has successful 
electroporation of M. avium been reported and in addition only very few of the 
genetic markers work efficiently in this species (Foley-Thomas et al., 1995). For 
these reasons, many aspects of gene regulation as well as of the physiology and 
pathogenicity of these mycobacteria remain to be elucidated. Kwon et al., (1995) has 
recently investigated the distribution of P-lactamase among mycobacteria. The 
activity of p-lactamase among slow growing mycobacteria was recorded to be 
maximum of 3+ for (18/18) species o fM  tuberculosis and (9/9) M. bovis screened. 
However, the p-lactamase activity was totally negative for (44/44) species of
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M. intracellulare and (75/75) forM  a\num (Kwon et ah, 1995). Also recently Batoni 
et al., (1998) successfully used lacZ as a cytoplasmic reporter gene under the control 
of the hsp60 promoter in recombinant M  avium.
In the present study, expression of a foreign antigen was successfiilly achieved in 
BCG using the DtxB gene. Using a western detection system, expression of the DtxB 
protein was detected in all constructed plasmids. The strength of the signal was 
similar for each plasmid except for a plasmid with only the 18-kDa promoter and 
here only a faint band was detected. The 18-kDa promoter is thought to be 
upregulated in vivo, however, this upregulation was not seen in this study when using 
p-lactamase as the reporter gene in rBCG infected mouse macrophage J-774.
Two previous studies have addressed the issue of targeting a heterologous antigen to 
various compartments of BCG and analysing the influence on its immunogenicity 
(Langermann et al., 1994; Stover et al., 1993). The antigen used was a lipoprotein 
from Borrelia burgdorferi. The best producing and most immunogenic strains were 
those where the foreign gene was fused to a sequence encoding a mycobacterial 
lipoprotein signal, thus targeting the produced protein to a “natural” compartment, 
the BCG membrane. Recently Himmelrich et al., (2000) expressed the E. coli MalE 
antigen in several constructed rBCGs. The E. coli MalE expression was much higher 
when the antigen was exported. Stronger and more rapid immune responses were 
induced by rBCG strains with the highest levels of secreted MalE compared to 
cytoplasmic or membrane constructs. Their studies suggest that immunogenecity 
correlates with the level of antigen production.
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Analysis o f the hsp60 promoter deletion in rBCG
Deletion of nucleotide sequences was a major problem when using the hsp60 
promoter driving a foreign gene in the plasmid-bome expression vector. Using three 
commonly used substrains of BCG, this study concluded that with the BCG Tokyo 
substrain both the rate and the degree of deletion were significantly less than those of 
the BCG Pasteur or BCG Moreau. Experiments to assess plasmid stability revealed 
BCG Tokyo to be superior, further examination of this substrain is warranted. By 
recovering plasmid DNA from many rBCG substrains and sequencing the 
transformed plasmids, this study determined that the deletion always started within 
the hsp60 promoter. Furthermore, a specific short region of nucleotide within the 
hsp60 promoter corresponding to the first transcriptional site of the M. bovis hsp60 
promoter was found to be common with all deletions in all three BCG substrains. 
This region is located between 160 bp to260 bp upstream of the hsp60 translational 
start codon. It would be interesting to see, firstly, whether the deletion will cease in 
hsp60 promoter region after the initial deletion has occurred, and secondly, whether 
the activity of the hsp60 promoter will be altered as a result of this mutation 
demonstrated by using a reporter gene such as lacZ.
Now, the ideal vaccine candidate among these plasmid constructs can be selected by 
screening based on their evaluation in animal models. Therefore, in principle any 
candidate foreign gene can be introduced and expressed at various modes and levels 
in BCG using the system described in this study. This strategy thus makes it feasible 
to express any antigen in BCG to elicit an optimal immune response. This, 
undoubtedly, will significantly extend the scope of the rBCG approach for the
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development of vaccines against other infections. Recent studies have demonstrated 
that rBCG expressing protective viral or bacterial antigens may induce strong cellular 
immune responses and under some circumstances good antibody responses. Thus, 
the rBCG approach with the strategy described here represents an attractive 
candidate for the development of live recombinant vaccine against infections of 
mycobacteria and other pathogens.
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